Nothing Special   »   [go: up one dir, main page]

WO2005039597A2 - Immunemodulating oligosaccharides - Google Patents

Immunemodulating oligosaccharides Download PDF

Info

Publication number
WO2005039597A2
WO2005039597A2 PCT/NL2004/000750 NL2004000750W WO2005039597A2 WO 2005039597 A2 WO2005039597 A2 WO 2005039597A2 NL 2004000750 W NL2004000750 W NL 2004000750W WO 2005039597 A2 WO2005039597 A2 WO 2005039597A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
group
ougosaccharide
composition
neutral
Prior art date
Application number
PCT/NL2004/000750
Other languages
French (fr)
Other versions
WO2005039597A3 (en
Inventor
Bernd Stahl
Laura M'rabet
Arjan Paul Vos
Johan Garssen
Günther Boehm
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34524733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005039597(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK06111971T priority Critical patent/DK1733730T3/en
Priority to CA2542996A priority patent/CA2542996C/en
Priority to JP2006536469A priority patent/JP4943853B2/en
Priority to BRPI0415699-4A priority patent/BRPI0415699A/en
Priority to NZ546785A priority patent/NZ546785A/en
Priority to EP04793675A priority patent/EP1675595A2/en
Priority to US10/576,834 priority patent/US8557794B2/en
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Priority to CN2004800312436A priority patent/CN1871015B/en
Priority to DK06115301T priority patent/DK1721612T3/en
Priority to AU2004283628A priority patent/AU2004283628B2/en
Priority to EP10186333.0A priority patent/EP2305269B1/en
Publication of WO2005039597A2 publication Critical patent/WO2005039597A2/en
Publication of WO2005039597A3 publication Critical patent/WO2005039597A3/en
Priority to AU2010235987A priority patent/AU2010235987A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a method for the treatment and/or prevention of immune diseases, said method comprising the administration of oligosaccharides.
  • Thl cells predominantly produce cytokines, which stimulate a cellular immune response (IFN- ⁇ , IL-12, IL-2).
  • Th2 cells predominantly produce IL-4, IL-5 and IL-10.
  • eosinophils i.e., leukocytes that accept an eosin stain
  • Thl- and Th2-related cytokines act antagonistically and the Thl/Th2 responses are under normal physiological circumstances in a well-controlled balance. Neither the Th 1 nor the Th2 response prevails. If in disbalance, the dominance of one of Thl or Th2 immune responses play a role in or is responsible for several pathological conditions.
  • Th 1 immune response eventually can lead to autoimmunity, the breakdown of material of the individuals own body, e.g. insulin dependent diabetes ellitus, multiple sclerosis, Crohn's disease, Pemphigus vulgaris, autoimmune thrombocytopenic purpura, autoimmune hemolytic anemia.
  • Th 2 response leads to extreme sensitivity towards foreign components which should not lead to any immunological reaction, e.g. allergies and related diseases such as atopic dermatitis, asthma, occupational asthma, food allergy (e.g. cows milk allergy, apple allergy, peanut and other nut allergies, lupine allergy), allergic rhinitis (e.g. pollen allergy), dust mite allergy and other forms of hypersensitivity like systemic anaphylaxis and acute urticaria.
  • allergies and related diseases such as atopic dermatitis, asthma, occupational asthma, food allergy (e.g. cows milk allergy, apple allergy, peanut and other nut allergies, lupine allergy), allergic rhinitis (e.g. pollen allergy), dust mite allergy and other forms of hypersensitivity like systemic anaphylaxis and acute urticaria.
  • a relative shift towards an increased Th 2 response and/or reduced Thl response is found under circumstances of stress of any sort, which consequently results in a bias towards a Th 2 response.
  • Such relative shift is for example observed in immunosenescence, cancer patients, chronic infections, an overload of exercise, social conflicts or high work loads, exposure to toxic components or radiation and metabolic stress leading to malnutrition, cachexia or malnutrition caused by anorexia.
  • Bifidogenic effects are held responsible for e.g. reduction and/or prevention of bacterial infection. It is known that oUgosacchandes can display bifidogenic effects.
  • Acid oligosaccharides have been described to have advantageous effects.
  • WO 02/42484 describes esterified pectin hydrolysates for the treatment of infection and/or the prevention of adhesions of harmful substances to eukaryotic cells.
  • DE 4223613 describes a process for the preparation of unsaturated uronides from pectin-like substances through anaerobic fermentation, using e.g pectate lyase. The preparation can be used for the medical treatment of heavy metal intoxication.
  • EP 1105002 describes a prebiotic composition comprising transgalactooligosaccharides, inulin and galacturonic acid oligosaccharides.
  • US 6576251 describes a combination of sialyated oligosaccharide (disialolacto-N-tetraose) and galactooUgosaccharides, for the prophylaxis of symptoms connected with the adhesion of organisms such as influenza.
  • WO 01/60378 describes mixtures of unsaturated pectin hydrolysate and neutral oUgosaccharides for the prevention of adhesion of pathogens to epitheUal surfaces.
  • the present inventors have now surprisingly found that systemic markers for the function of the immune system are influenced by the administration of (acid) oligosaccharides.
  • This finding opens a new field of application of oUgosaccharides, particularly for diseases which at best can be treated by immune system modulation
  • modulation or “modulating” is intended an increase or decrease in a particular character, quaUty, activity, substance or response.
  • acid oUgosaccharides and neutral oligosaccharides are capable of stimulating the systemic immune response.
  • the present inventors also surprisingly found that the different oUgosaccharides have different stimulatory effects on the immune system. It was found that administration of acid oUgosaccharides (relatively) stimulates Thl response and lowers the Th2 cytokine release (e.g. IL-10, IL-4 and IL-5). It was also found that administration of a combination of acid oUgosaccharide and neutral oUgosaccharide synergistically stimulates the immune-system, particularly by lowering the Th2 response and increasing the Thl response.
  • oUgosaccharides can be advantageously used to restore disbalance in the Thl/Th2 responses and for the treatment and prevention of disorders which are associated with Thl/Th2 disbalance.
  • the administration of acid oligosaccharide, optionally combined with neutral oUgosaccharide is able to restore Thl/Th2 disbalance and/or maintain a favorable Thl/Th2 balance.
  • acid oUgosaccharide, preferably in combination with the neutral oligosaccharide is capable of stimulating Thl response.
  • the present inventors also beUeve that the administration of acid- and neutral oUgosaccharides stimulates Th3, i.e. enhances the regulatory T cell activity. It is perceived that the stimulation of Thl response is achieved in part by inhibiting Th2 response.
  • the present invention provides a method for
  • the method comprises the administration of acid oUgosaccharide, preferably acid- and neutral oligosaccharide, more preferably acid oligosaccharide and two chemically distinct neutral oUgosaccharides.
  • acid oUgosaccharide has a beneficial effect on inflammatory cytokines (Thl response).
  • the combination of acid oUgosaccharide and neutral oUgosaccharide has a beneficial effect on inflammatory cytokines (Th2 response).
  • the present invention relates to a method for the treatment and or prevention of an immune system related disorder in a mammal, said method comprising administering to said mammal a composition comprising a therapeutically effective amount of acid oUgosaccharide and neutral oUgosaccharide, i.e. the use of acid oUgosaccharide and neutral oUgosaccharide in the manufacture of a composition for the treatment and/or prevention of an immune system related disorder in a mammal.
  • the present invention relates to the use of acid oUgosaccharide and neutral oUgosaccharide in the manufacture of a composition for enhancing the immune response in a mammal and/or a method for modulating the immune system.
  • the present invention relates to a food composition
  • a food composition comprising between 5 and 50 en% Upid, between 10 and 60 en% protein, between 15 and 90 en% carbohydrate, and preferably a caloric density between 0.5 and 2 kcal/ml, acid oUgosaccharide and neutral oUgosaccharide, wherein said acid oUgosaccharide comprises at least one terminal uronic acid unit; and said neutral oUgosaccharide is selected from the group consisting of cellobiose, cellodextrin, B-cyclodextrin, indigestible dextrin, gentiooligosaccharide, glucooUgosaccharide, isomaltooligosaccharide, isomaltose, isomaltriose, panose, leucrose, palatinose, theanderose, D-agatose, D-Z x ⁇ -hexulose, lactosucrose, ⁇
  • the present invention relates to a method for the treatment and/or prevention of an immune system related disorder selected from autoimmune disorders, hereditary or conditional induced immunodeficiency, support for vaccinations, allergy Type 1, allergy Type 2 and allergy Type 3, said method comprising administering to said mammal a composition comprising a therapeutically effective amount of acid oUgosaccharide.
  • Some diseases that are thought to be caused/mediated in substantial part by Th2 immune response, IL-4/IL-5 cytokine induction, and/or eosinophiUa include asthma, allergic rhinitis, systemic lupus erythematosis, Ommen's syndrome (hypereosinophiUa syndrome). These are examples of non- viral and non-tumor, Th2 mediated diseases for which effective treatment with the method of the present invention clearly could not have been predicted. Particularly preferred methods of the present invention are for the treatment of diseases associated with eosinophiUa, such as asthma and allergic rhinitis.
  • a therapeutically effective amount for a particular disorder can be routinely determined by one of skill in the art via dose-finding studies.
  • the present invention provides a method for modulating and/or enhancing the immune system, said method comprising the administration of acid- and neutral oUgosaccharides.
  • This method can be suitably used in a method for balancing the Thl/ Th2 response, in particular by simulating the Thl response.
  • compositions containing the present oUgosaccharide(s) which are advertised to e.g. simulate maturation of the immune system, enhance the resistance to pathogens by enhancing the immune system and or support the immune system are part of the present invention.
  • the present invention provides a method for the treatment and/or prevention of an immune system related disorder, said method comprising administering to said mammal a composition comprising a therapeutically effective amount of acid oUgosaccharide.
  • the present invention provides a method of enhancing the immune response in a mammal said method comprising administering to the mammal a composition comprising acid oUgosaccharide, optionally combined with neutral oUgosaccharide. It was particularly surprising that the enteral administration of the present oUgosaccharides provides the beneficial systemic effects. Hence, the present method preferably comprises the enteral, even more preferably the oral administration of acid oUgosaccharide or acid- and neutral oUgosaccharide.
  • the method of the invention relates to the administration of oUgosaccharides to infants, preferably humans in the age of 0 to 6 years, preferably in the age of between 0 and 1 year.
  • the present method can be suitably used to restore this disbalance in this population.
  • Administration of the acid oUgosaccharide, preferably combined with the neutral oUgosaccharide is also beUeved to improve maturation of the (gastro)intestinal tract of the newboms, making the present method and composition particularly suitable for administration to pre-term infants.
  • the present method relates to the stimulation of the maturation of the immune system in human subjects between the age of 0-6 year, preferably between 0 and 1 year.
  • compositional features such as protein, carbohydrate, Upid, osmolality, viscosity and caloric density of a composition which can be suitably used in this method are described below.
  • the immune system related disorder is preferably selected from autoimmune disorders, hereditary or conditional induced immunodeficiency, support for vaccinations, allergy Type 1, allergy Type 2, allergy Type 3 and allergy Type 4.
  • Autoimmune disorders which can suitably be treated include systemic lupus erythematosus, chronic glomerulonephritis, polyarteritis nodosa, poststreotococcal acute glomerulonephritis, Graves' disease, myasthenia gravis, insuUne resistant diabetes, hashimoto's thyroiditis, haemolytic anaemia, pernicious anaemia, Goodpasture's syndrome, pemphigus vulgaris, autoimmune thrombocytopenia pupura, acute rheumatic fever, mixed essential cryoglobulinemia, autoimmune preniciopus anemia, autoimmune Addison's disease, VitiUgio, hypoglycemia, neonatal lupus rash, IDDM (insuUn dependent diabetes melUtus), rheumatoid arthritis, multiple sclerosis, psoriasis, scleroderma, Crohn's disease, IBD (inflammatory bowel disease), neuro
  • Conditions of hereditary or conditional induced immunodeficiency which can suitably be treated include immunosenescence, autism, malnutrition caused by chronic diseases, such as cancer, COPD (chronic obstructive pulmonary disease), AIDS, arthritis, diabetes, anorexia, cachexia, dysphagea, kidney failure, radiation, patients suffering from chronic ulcerations and stress in more detail stress after social stress, chronic infection or cigarette smoke, air pollution, radiation, chemotherapy.
  • the present invention particularly provides a method for the treatment and/or prevention AIDS and/or HIV infection, said method comprising the enteral administration of the present acid oUgosaccharides, preferably in combination with the present neutral oUgosaccharides.
  • the present invention also provides a method for the treatment and/or prevention of diarrhea in subjects suffering from ADDS and/or HIV infection, said method comprising enterally administering the present acid oUgosaccharides, preferably in combination with the present neutral oUgosaccharides.
  • the present (acid) oUgosaccharide is preferably provided to the subject suffering from AIDS and/or HTV infection in a nutritional matrix, i.e. a composition comprising fat, protein and carbohydrate.
  • Allergies which can suitably be treated include Type 1 allergies; atopy, asthma, hay fever, eczema, food allergy, drug allergy.
  • Type 2 allergies haemolytic disease of new borns, autoimmune haemolytic anaemia, ankylosing spondyUtis, acute anterior uveitis.
  • Type 3 allergies arthus reaction, serum sickness.
  • Type 4 allergies delayed type hypersensitivity, contact sensitivity, ceUac disease. It was also found that the present method can suitably be used to support vaccination processes, e.g. enhance the effects of a vaccination process. These are included in the term immune system related disorders.
  • the acid oUgosaccharides are preferably (orally) administered before, during and/or after vaccination.
  • vaccinations for diptheria-tetanus- pertussis, poUo vaccine, measles/mumps/rubella, pneumococcal conjugate, haemophilus B conjugate, hepatitis B, hepatitis A, varicella, influenza can suitably be enhanced.
  • the present method relates to the treatment and or prevention of malnutrition, atopy, asthma or COPD.
  • the present invention also relates to the use of acid oUgosaccharides in the manufacture of a composition for the treatment and/or prevention of an immune system related disorder selected from autoimmune disorders, hereditary or conditional induced immunodeficiency (preferably not AIDS), support for vaccinations, allergy Type 1, allergy Type 2 and allergy Type 3.
  • an immune system related disorder selected from autoimmune disorders, hereditary or conditional induced immunodeficiency (preferably not AIDS), support for vaccinations, allergy Type 1, allergy Type 2 and allergy Type 3.
  • the term acid oUgosaccharide refers to oUgosaccharides comprising at least one acidic group selected from the group consisting of N-acetylneuraminic acid, N- glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group.
  • the acid oUgosaccharide preferably is a polyhexose.
  • at least one of the aforementioned acid groups is situated at the terminal hexose unit of the acid oUgosaccharide.
  • the acid oUgosaccharide has the structure as depicted in Fig.l, wherein the terminal hexose (left) preferably comprises a double bond.
  • the acid oUgosaccharide contains a carboxylic acid at the terminal hexose unit, wherein said carboxyUc acid group may be free or esterified.
  • carboxyUc acid group may be free or esterified.
  • Methods for the manufacture of esterified pectin hydrolysates that can be suitably used in the present method and composition are provided in WO 01/60378 and/or WO02/42484, which are hereby incorporated by reference.
  • the hexose units other than the terminal hexose unit(s) are preferably uronic acid units, even more preferably galacturonic acid units.
  • the carboxyUc acid groups on these units may be free or (partly) esterified, and preferably at least 10% is methylated (see below).
  • R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy; and at least one selected from the group consisting of R 2 , R 3 , R 4 and R 5 represents N- acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxyUc acid, sulfuric acid group and phosphoric acid group, and the remaining of R 2 , R 3 , R 4 and R 5 representing hydroxy and/or hydrogen.
  • R 2 , R 3 , R4 and R 5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxyUc acid, sulfuric acid group or phosphoric acid group, and the remaining represent hydroxy and/or hydrogen.
  • R , R , R 4 and R5 represents free or esterified carboxyUc acid and the remaining of R 2 , R 3 , R 4 and R5 representing hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit.
  • n is an integer between 1-5000.
  • the hexose unit(s) is an uronic acid unit.
  • Ri, R 2 and R 3 represent hydroxy, R 4 represent hydrogen, R 5 represents carboxyUc acid,
  • n is any number between 1 and 250, preferably between 1 and 10 and the hexose unit is galacturonic acid.
  • the detection, measurement and analyses of the preferred acid oUgosaccharides as used in the present method are given in appUcant's earlier patent application relating to acid oUgosaccharides, i.e. WO 0/160378, which is hereby incorporated by reference.
  • the acid oUgosaccharide has one, preferably two, terminal uronic acid units, which may be free or esterified.
  • the terminal uronic acid unit is selected from the group consisting of galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and alturonic acid. These units may be free or esterified.
  • the terminal hexose unit has a double bond, which is preferably situated between the C 4 and C 5 position of the terminal hexose unit.
  • one of the terminal hexose units comprises the double bond.
  • the terminal hexose e.g. uronic acid
  • Fig. 2 Preferred terminal hexose acid group
  • R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy (see above); and at least one selected from the group consisting of R 2 , R 3 , R 4 and R 5 represents N- acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxyUc acid, sulfuric acid group and phosphoric acid group, and the remaining of R 2 , R 3 , R/ t and R 5 representing hydroxy and/or hydrogen.
  • R 2 , R 3 , t and R 5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxyUc acid, sulfuric acid group and phosphoric acid group, and the remaining of R 2 , R 3 , R t and R 5 represent hydroxy and/or hydrogen.
  • R 2 , R 3 , R 4 and R 5 represents free or esterified carboxyUc acid and the remaining of R 2 , R 3 , R4 and R 5 represent hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit.
  • n is an integer between 1-5000 representing the number of hexose units said hexose units preferably being uronic acid, even more preferably being galacturonic acid units.
  • the carboxyUc acid groups on these units may be free or (partly) esterified, and are preferably at least partly methylated.
  • R 2 and R 3 represent hydroxy
  • R 4 represent hydrogen
  • R 5 represents free or esterified carboxylic acid.
  • a mixture of acid oligosaccharides is used, which have a different DP and/or comprise both unsaturated and saturated terminal hexose unit.
  • At least 5%, more preferably at least 10%, even more preferably at least 25% of the terminal hexose units of the acid oUgosaccharide unsaturated hexose unit (see e.g.
  • each individual acid oligosaccharide preferably comprises only one unsaturated terminal hexose unit, preferably no more than 50% of the terminal hexose units is an unsaturated hexose unit (i.e. comprises a double bond).
  • a mixture of acid oUgosaccharides preferably contains between 2 and 50% unsaturated hexose units based on the total amount of hexose units, preferably between 10 and 40%.
  • the acid oligosaccharide as used in the present method has a degree of polymerisation (DP) between 1 and 5000, preferably between 1 and 1000, more preferably between 2 and 250, even more preferably between 2 and 50, most preferably between 2 and 10. If a mixture of acid oUgosaccharides with different degrees of polymerisation is used, the average DP of the acid oUgosaccharide mixture is preferably between 2 and 1000, more preferably between 3 and 250, even more preferably between 3 and 50. See also Fig.l, wherein the sum of "n" and the terminal unit (i.e. n+1) represents the degree of polymerisation.
  • the acid oUgosaccharide may be a homogeneous or heterogeneous carbohydrate.
  • the acid oUgosaccharides used in the invention are preferably prepared from pectin, pectate, alginate, chondroitine, hyaluronic acids, heparine, heparane, bacterial carbohydrates, sialoglycans, fucoidan, fucooUgosaccharides or carrageenan, preferably from pectin or alginate.
  • the acid oUgosaccharides may be prepared by the methods described in WO 01/60378, which is hereby incorporated by reference.
  • Alginates are Unear unbranched polymers containing ⁇ -(l-> 4)-Unked D-mannuronic acid and ⁇ -(l- 4)-tinked L-guluronic acid residues with a wide range of average molecular weights (100 - 100000 residues).
  • Suitable sources of alginate include seaweeds and bacterial alginates.
  • Pectin is divided into two main categories: high methoxylated pectin, which is characterised by a degree of methoxylation above 50% and low methoxylated pectin having a degree of methoxylation below 50%.
  • degree of methoxylation also referred to as DE or “degree of esterification”
  • the present acid oUgosaccharide is preferably prepared from high methoxylated pectin.
  • the acid oUgosaccharides are preferably characterised by a degree of methoxylation above 20%, preferably above 50 % even more preferably above 70%.
  • the acid oUgosaccharides have a degree of methylation above 20%, preferably above 50 % even more preferably above 70%.
  • the acid oUgosaccharide is preferably administered in an amount of between 10 mg and 100 gram per day, preferably between 100 mg and 50 grams per day, even more between 0.5 and 20 gram per day.
  • Neutral oligosaccharides are preferably administered in an amount of between 10 mg and 100 gram per day, preferably between 100 mg and 50 grams per day, even more between 0.5 and 20 gram per day.
  • neutral oUgosaccharides refers to saccharides which have a degree of polymerisation of monose units exceeding 2, more preferably exceeding 3, even more preferably exceeding 4, most preferably exceeding 10, which are not or only partially digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach) but which are fermented by the human intestinal flora and preferably lack acidic groups.
  • the neutral oligosaccharide is structurally (chemically) different from the acid oligosaccharide.
  • neutral oUgosaccharides as used in the present invention preferably refers to saccharides which have a degree of polymerisation of the oligosaccharide below 60 monose units, preferably below 40, even more preferably below 20, most preferably below 10.
  • monose units refers to units having a closed ring structure, preferably hexose, e.g. the pyranose or furanose forms.
  • the neutral oUgosaccharide preferably comprises at least 90%, more preferably at least 95% monose units selected from the group consisting of mannose, arabinose, fructose, fucose, rhamnose, galactose, ⁇ -D-galactopyranose, ribose, glucose, xylose and derivatives thereof, calculated on the total number of monose units contained therein.
  • Suitable neural oUgosaccharides are preferably fermented by the gut flora.
  • the oUgosaccharide is selected from the group consisting of: cellobiose (4-O- ⁇ -D-glucopyranosyl-D-glucose), cellodextrins ((4-O- ⁇ -D- glucopyranosyl) n -D-glucose), B-cyclodextrins (CycUc molecules of ⁇ -l-4-linked D- glucose; ⁇ -cyclodextrin-hexamer, ⁇ -cyclodextrin-heptamer and ⁇ -cyclodextrin-octamer), indigestible dextrin , gentiooUgosaccharides (mixture of ⁇ -1-6 linked glucose residues, some 1-4 linkages), glucooUgosaccharides (mixture of ⁇ -D-glucose), isomaltooU
  • the neutral oligosaccharide is selected from the group consisting of fructans, fructooUgosaccharides, indigestible dextrins galactooUgosaccharides (including transgalactooUgosaccharides), xylooligosaccharides, arabinooUgosaccharides, glucooUgosaccharides, mannooligosaccharides, fucooUgosaccharides and mixtures thereof.
  • the neutral oUgosaccharide is selected from the group consisting of fructooUgosacchararides, galactooUgosaccharides and transgalactooUgosaccharides.
  • Suitable oUgosaccharides and their production methods are further described in Laere K.J.M. (Laere, K.J.M., Degradation of structurally different non-digestible oUgosaccharides by intestinal bacteria: glycosylhydrolases of Bi. adolescentis. PhD-thesis (2000), Wageningen Agricultural University, Wageningen, The Netherlands) the entire content of which is hereby incorporated by reference.
  • TransgalactooUgosaccharides are for example sold under the trademark VivinalTM (Borculo Domo Ingredients, Netherlands).
  • Indigestible dextrin which may be produced by pyrolysis of corn starch, comprises ⁇ (l- ⁇ 4) and ⁇ (l->6) glucosidic bonds, as are present in the native starch, and contains l->2 and l- 3 Unkages and levoglucosan. Due to these structural characteristics, indigestible dextrin contains well-developed, branched particles that are partially hydrolysed by human digestive enzymes.
  • transgalactooUgosaccharide is available from Yakult Honsha Co., Tokyo, Japan.
  • Soybean oUgosaccharide is available from Calpis Corporation distributed by Ajinomoto U.S.A. Inc., Teaneck, NJ.
  • the present method comprises the administration of 2 chemically distinct oUgosaccharides. It was found that the administration of acid oUgosaccharides combined with two chemically distinct neutral oUgosaccharides provides an optimal effect.
  • the present method comprises the administration of an
  • - acid oUgosaccharides see above
  • - galactose based neutral oUgosaccharide >50 % of the monose units are galactose, preferably selected from the group consisting of galactooUgosaccharide and transgalactooUgosaccharide;
  • the present method comprises the administration of 2 structurally (chemically) distinct oUgosaccharides, wherein two structurally (chemically) distinct oligosaccharides are differentiated by their type of glycosidic Unkages.
  • the method comprises the administration of two chemically distinct neutral oUgosaccharides, said chemically distinct oUgosaccharides having a different DP and/or different average DP, preferably different average DP.
  • administering chemically distinct neutral oUgosaccharides with different average DP provides an even more optimal immune-modulating effect.
  • galactose based neutral oUgosaccharide has an average DP between 2 and 10
  • fructose and/or glucose based neutral oUgosaccharides have an average DP between 10 and 60.
  • the neutral oligosaccharide is preferably administered in an amount of between 10 mg and 100 gram per day, preferably between 100 mg and 50 grams per day, even more preferably between 0.5 and 20 gram per day.
  • the present method comprises the administration of a therapeutically effective amount of acid oUgosaccharides and neutral oUgosaccharides.
  • the mixture of acid- and neutral oUgosaccharides is preferably administered in an amount of between 10 mg and 100 gram per day, preferably between 100 mg and 25 grams per day, even more preferably between 0.5 and 20 gram per day.
  • a preferred combination of acid oUgosaccharides and neutral oligosaccharides comprises the acid oUgosaccharides of Fig.2, wherein
  • R represents hydrogen, hydroxy or acid group, preferably hydroxy ; and one selected from the group consisting of R 2 , R 3 , 1 ⁇ and R 5 represents free or esterified carboxyUc acid and the remaining of R 2 , R 3 , R and R 5 represent hydroxy and/or hydrogen; and galactooUgosaccharide and/or transgalactooUgosaccharide.
  • the acid and neutral oligosaccharides are administered in a weight ratio of between 0.01:1 and 1:0.01, preferably in a weight ratio of between 0.1:1 and 1: 0.1.
  • the present method further comprises the administration of long-chain polyunsaturated acid (LCPUFA).
  • LCPUFA long-chain polyunsaturated acid
  • the present method preferably comprises the administration of between 0.1 and 100 g LCPUFA per day, more preferably between 1 and 25 grams LCPUFA per day.
  • Uquid food includes dry food (e.g. powders) which are accompanied with instructions as to admix said dry food mixture with a suitable Uquid (e.g. water).
  • the present invention also relates to a nutritional composition which preferably comprising between 5 and 50 en% Upid, between 10 and 60 en% protein, between 15 and 90 en% carbohydrate and the present acid oUgosaccharides, preferably in combination with the neutral oUgosaccharides.
  • the present nutritional composition preferably contains between 10 and 30 en% Upid, between 15 and 40 en% protein and between 25 and 75 en% carbohydrate (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation).
  • Such food preferably is in Uquid form and has a Umited viscosity. It was found that the foods containing the acid oUgosaccharides, optionally combined with the neutral oUgosaccharides, provides a Uquid nutrition with sufficiently low viscosity so it can be appUed as e.g. Uquid baby foods and Uquid cUnical food which can be fed through a tube or a straw, while retaining the low viscosity.
  • the present composition has a viscosity below 600 mPas, preferably below 250 mPas, more preferably below 50 mPas, most preferably below 25 mPas at a shear rate of 100s "1 at 20°C.
  • viscosity used in the present document, this refers to the physical parameter which is determined according to the following method:
  • the viscosity may be determined using a Carri-Med CSL rheometer.
  • the used geometry is of conical shape (6 cm 2 deg acrytic cone) and the gap between plate and geometry is set on 55 ⁇ m.
  • a linear continuous ramp shear rate is used from 0 to 150 s "1 in 20 seconds.
  • the vegetable Upid is preferably at least one selected from the group consisting of soy oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil and lecithins.
  • Animal fats such as milk fats may also be added if desired.
  • the proteins used in the nutritional preparation are preferably selected from the group of non-human animal proteins (such as milk proteins, meat proteins and egg proteins), vegetable proteins (such as soy protein, wheat protein, rice protein, and pea protein), free amino acids and mixtures thereof.
  • non-human animal proteins such as milk proteins, meat proteins and egg proteins
  • vegetable proteins such as soy protein, wheat protein, rice protein, and pea protein
  • free amino acids and mixtures thereof such as soy protein, wheat protein, rice protein, and pea protein
  • Cow milk proteins such as casein and whey proteins are particularly preferred.
  • a source of digestible carbohydrate may be added to the nutritional formula. It preferably provides about 40% to about 80% of the energy of the nutritional composition. Any suitable (source of) carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup soUds, and maltodextrins, and mixtures thereof.
  • the present composition is preferably substantially free of viable bifinogenic bacteria.
  • Stool irregularities e.g. hard stools, insufficient stool volume, diarrhoea
  • Stool irregularities e.g. hard stools, insufficient stool volume, diarrhoea
  • osmolaUty between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg.
  • the liquid food does not have an excessive caloric density, however still provides sufficient calories to feed the subject.
  • the liquid food preferably has a caloric density between 0.1 and 2.5 kcal/ml, even more preferably a caloric density of between 0.5 and 1.5 kcal/ml.
  • Such infant formula preferably comprises Upid, protein and carbohydrate and is preferably administered in Uquid form.
  • liquid food as used in the present invention includes dry food (e.g. powders) which are accompanied with instructions as to admix said dry food mixture with a suitable Uquid (e.g. water).
  • the present invention also relates to an infant formula which preferably comprises between 5 and 60 en% Upid, between 5 and 40 en% protein, between 15 and 90 en% carbohydrate and the present combination of oligosaccharides and LC-PUFA's.
  • the present infant formula contains between 30 and 60 en% Upid, between 6 and 15 en% protein and between 25 and 75 en% carbohydrate (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation).
  • a combination of vegetable Upids and at least one oil selected from the group consisting of fish oil and omega-3 containing vegetable, algae or bacterial oil is used.
  • the proteins used in the nutritional preparation are preferably selected from the group of non-human animal proteins (such as milk proteins, meat proteins and egg proteins), vegetable proteins (such as soy protein, wheat protein, rice protein, and pea protein), free amino acids and mixtures thereof.
  • Cow milk derived nitrogen source particularly cow milk protein proteins such as casein and whey proteins are particularly preferred.
  • a source of digestible carbohydrate may be added to the nutritional formula. It preferably provides about 40% to about 80% of the energy of the nutritional composition. Any suitable (source of) carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup soUds, and maltodextrins, and mixtures thereof.
  • the present infant formula contains 7 to 12 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat.
  • the protein of the infant formula is preferably selected from the group consisting of hydrolyzed milk protein (e.g. hydrolyzed casein or hydrolyzed whey protein), vegetable protein and/or amino acids. The use of these proteins further reduced the allergic reactions of the infant.
  • Stool irregularities e.g. hard stools, insufficient stool volume, diarrhea
  • stool problems e.g. diarrhea
  • osmolaUty between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg.
  • the present invention also provides a composition which is particularly suitable for use in the present method.
  • This composition has a high similarity with natural human milk, both in functionaUty and molecular structure. Hence, the composition is particularly suitable as an infant formula.
  • the present composition contains fat, carbohydrate, protein; and between 0.5 and 1 gram soluble indigestible oUgosaccharides per 100 ml Uquid product, preferably between 0.7 and 0.9 gram/100 ml.
  • composition contains, per 100 ml Uquid product, between 0.4 and 0.7 gram transgalactooUgosaccharides (indigestible [galactose] n -glucose comprising ⁇ -Unked saccharides; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, ...., 59 ,60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10); and between 0.01 and 0.1 gram inulin (indigestible polysaccharide carbohydrate comprising a chain of at least 10 ⁇ - linked fructose units); and between 0.04 and 0.3 gram acid oligosaccharides as depicted in Figure 2.
  • the present Uquid product can be suitably prepared by a consumer from a powdered product.
  • the present Uquid product preferably contains the ingredients and has the characteristics as described herein above and below and can be favorably used in the methods described herein.
  • the acid oUgosaccharide is preferably included in the present composition according to the invention in an amount exceeding 0.1 wt.%, preferably exceeding 0.2 wt.%, more preferably exceeding 0.5 wt.% and even more preferably exceeding 1 wt.% based on the total dry weight of the composition.
  • the present composition preferably has an oUgosaccharide content below 20 wt.%, more preferably below 10 wt.% even more preferably below 5 wt.%.
  • the neutral oUgosaccharide is preferably included in the present composition according to the invention in an amount exceeding 0.1 wt.%, preferably exceeding 0.2 wt.%, more preferably exceeding 0.5 wt.% and even more preferably exceeding 1 wt.% based on the total dry weight of the composition.
  • the present composition preferably has an oUgosaccharide content below 20 wt.%, more preferably below 10 wt.% even more preferably below 5 wt.%.
  • the present composition was found to synergistically stimulate the immune system.
  • the present composition can be suitably used in a method for the treatment and/or prevention of infection, said method comprising orally administering to a human, preferably an infant, the present composition.
  • the present composition By stimulating the immune system and by promoting a healthy intestinal flora, the present composition also has a systemic anti- infective effect.
  • the present acid oUgosaccharides preferably combined with the present neutral oUgosaccharides can be advantageously used for the treatment and/or prevention of intestinal infections and/or respiratory tract infections.
  • the oUgosaccharide(s) are orally administered in a food matrix as described above.
  • the present invention provides a method for the treatment of these subjects, said method comprising the enteral administration of the present acid oligosaccharides, preferably in combination with the present neutral oligosaccharides.
  • the present (acid) oligosaccharide is preferably provided to these subjects in a nutritional matrix, i.e. a composition comprising fat, protein and carbohydrate.
  • DTH delayed-type hypersensitivity
  • Acid oUgosaccharides used, with an average DP between 2 and 10, were obtained by the method described in WO 02/42484 (see example 1) . Diets containing 1 wt.%, 2.5 wt.%, 5 wt.% and 10% wt.% AcOl based on total weight of the diet were tested. Neutral oUgosaccharide mixture (GF) containing galactooUgosaccharides (GOS) (Vivinal-GOSTM (Borculo Domo Ingredients, Netherlands) and fructooUgosaccharides (FOS) (Raftiline HPTM, Orafti, Tienen, Belgium) were used in a weight ratio GOS:FOS of 9:1.
  • GOS galactooUgosaccharides
  • mice Female, 6 weeks old C57B1/6 mice (Harlan Nederland BV, Horst, the Netherlands) were group-housed under a regular 12 hours Ught/dark regime. Group size was 10 animals per group and 3 animals in the negative control groups. The animals were given semi- synthetic diets (Research Diet Services, Wijk bij Duurstede, the Netherlands). Control diets were made to the AIN93G specifications (Reeves et al (1993) Development and Testing of the AIN93 purified diets for rodents: results on growth kidney calcification and bone mineralisation in rats and mice. J Nutrition 123(11): 1923-31), oUgosaccharide supplemented diets were based on these specifications.
  • Carbohydrate content of the supplemented diets were kept constant by the exchange of total carbohydrates for the oUgosaccharides on a weight basis.
  • the separate carbohydrate components were substituted respective to their normal ratio in the diet.
  • the carbohydrates in the normal diet consist of cornstarch (40% of total weight), dextrinized cornstarch (13.2%), sucrose (10%) and cellulose (5%).
  • Vaccinations were started after a period of two to four weeks of adaptation to the new housing and diets.
  • a blood sample was collected prior to vaccination.
  • the first vaccination was administered subcutaneously.
  • a blood sample was collected (day 21) and a booster vaccination was given (day 22).
  • basal ear thickness was measured with a Digimatic outside micrometer (Mitutoyo, Veenendaal, the Netherlands) and a delayed-type hypersensitivity (DTH) response was induced by injecting antigen solution i.e. (intracutaneous) in the mouse ear pinnae. 24 h therafter (day 32), the DTH response was measured, a bloodsample was taken and the mice were sacrificed.
  • DTH delayed-type hypersensitivity
  • Spleens were isolated and prepared for ex-vivo restimulations.
  • the vaccinations consisted of a 100 ⁇ l i.e. (intracutaneous) injection of a 1:1 mix of antigen solution and Stimune adjuvant (Specol, Cedi-diagnostics BV, Lelystad, the Netherlands).
  • the antigen solution was a 1:100 dilution of Influvac 2002/2003 (Solvay Pharmaceuticals, Weesp, the Netherlands) in PBS .
  • Influvac is a trivalent protein vaccine, containing 3x30 ⁇ g/ml haemagglutinin of three different influenza strains.
  • mice were i.e. injected with 25 ⁇ l dialysed Influvac in both ears as a DTH challenge.
  • Splenocytes were isolated from the spleens using fine-mesh cell strainers (Becton Dickinson, Erembodegem, Belgium). Red blood cells were lysed by 5 minutes incubation on ice. After washing with culture medium without phenol red, cells were counted (Coulter Counter, Beckman Coulter, the Netherlands) and kept on ice. Cultures were set up using 0.1 ⁇ g/ml dialysed Influvac as a stimulus. Cells were seeded in 96-well culture plates at 1*10 6 cells per well.
  • the culture medium consisted of RPMI- 1640 with HEPES buffer and 2 mM L-Glutamine (Invitrogen, Merelbeke, Belgium) with 10% fetal calf serum (FCS). Cultures were incubated for 5 days at 37°C at 5% CO 2 . Thereafter supernatants were harvested and frozen at -80°C until analysis. Cell proliferation was measured in parallel cultures by 3 H-thymidine incorporation, which was added to the cultures for the last 18 hours at 0.4 ⁇ Cu/well. After 5 days, the cells were harvested using a Filtermate harvester (Perkin Elmer, Zaventem, Belgium) and counted on a Micro-Beta counter (Perkin Elmer, Zaventem, Belgium). Radioactive decay was measured for 1 minute per well and the counts per minute (cpm) were recorded as a measure for proUferation speed.
  • FCS fetal calf serum
  • Cytokines were analysed in supernatants of Influvac stimulated cultures. IL-2, IL-5, IL-
  • IFN-gamma 10 and IFN-gamma were measured using the Bio-Plex system with a custom mixed beadset for the cytokines mentioned (Bio-Rad, Veenendaal, the Netherlands). Cytokines were measured according to the manufacturer's specifications. IL-4 was measured by ELISA using the Pharmingen OptEIA mouse IL-4 kit (Becton Dickinson, Erembodegem,
  • Results DTH response acid oligosaccharides The diets containing dosages of 1 wt.%, 2.5 wt.% and 5 wt.% AcOl induced a statistically significant increase in the DTH response, showing a dose-dependent increase (see Table 1). The observed effect is indicative for the advantageous use of acid oUgosaccharides in the present method.
  • DTH response acid and neutral oligosaccharides The combination of 1 wt.% GF and 1 wt.% AcOl induce a statistically significant increase in the DTH (see Table 2). As the effect is significantly higher than the DTH responses from diets containing the acid or neutral oUgosaccharides alone, these results are indicative for the synergistic effect provided by the administration of acid and neutral oUgosaccharides. The observed effect is indicative for the advantageous use of a combination of acid and neutral oligosaccharides in the present method.
  • Thl/Th2 balance Cytokine profiles after administration of acid oligosaccharides Cytokine profiles were measured in the culture supernatants of the influvac specific splenocytes. Data are presented as percentage relative to values of the vaccinated control group (i.e. receiving no oligosaccharides). Compared to controls, diets containing 2.5 wt.% and 5 wt.% AcOl resulted in a decrease in the Th2-related cytokines IL-4 , IL-5 and IL-10, while the Thl -related cytokines IL-2 was increased and IFN- ⁇ was not significantly lowered (see Table 4).
  • Th2 balance Cytokine profiles after administration of acid and neutral oligosaccharides Compared to controls, administration of a combination of 1 wt.% GT and 1 wt.% AcOl resulted in a decrease in the Th2-related cytokines IL-4, IL-5 and IL-10, while the Thl - related cytokines IL-2 and IFN- ⁇ were not lowered (see Table 4, wherein data are presented as percentage relative to values of the vaccinated control group (i.e. receiving no oUgosaccharides)).
  • Thl/Th2 balancing effect of a combination of acid- and neutral oligosaccharides is indicative for the advantageous use of acid oUgosaccharides in the present method, e.g. for the treatment and/or prevention of diseases with relatively low Thl immunity.
  • the IL-4/IFN ratio reflects the Th2/Thl balance.
  • a lower ratio is indicative for stimulation of Thl and/or inhibition of Th2, and in any case indicative for the Thl-Th2 balancing effect of the present oUgosaccharides.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pediatric Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

The present invention relates to a method for enhancing the immune system and the treatment and/or prevention of immune system related disorders in a mammal, particularly newborns, said method comprising the administration of acid oligosaccharide and neutral oligosaccharide. Food compositions suitable for use in the above method are also provided.

Description

IMMUNEMODULATING OLIGOSACCHARTOES
FIELD OF THE INVENTION
The present invention relates to a method for the treatment and/or prevention of immune diseases, said method comprising the administration of oligosaccharides.
BACKGROUND OF THE INVENTION
The immune system has different possible ways of reacting to an antigen. A decisive step for the type of immune response is the stimulation of different T-cell subpopulations. So called Thl cells predominantly produce cytokines, which stimulate a cellular immune response (IFN-γ, IL-12, IL-2). In contrast, Th2 cells predominantly produce IL-4, IL-5 and IL-10. These cytokines boost an IgE-mediated allergic reaction and inflammation and are thought as well to be involved with recruitment, proliferation, differentiation, maintenance and survival of eosinophils (i.e., leukocytes that accept an eosin stain), which can result in eosmophilia. Eosmophilia is a hallmark of many Th2 mediated diseases, such as asthma, allergy, and atopic dermatitis. Thl- and Th2-related cytokines act antagonistically and the Thl/Th2 responses are under normal physiological circumstances in a well-controlled balance. Neither the Th 1 nor the Th2 response prevails. If in disbalance, the dominance of one of Thl or Th2 immune responses play a role in or is responsible for several pathological conditions.
An excessive Th 1 immune response eventually can lead to autoimmunity, the breakdown of material of the individuals own body, e.g. insulin dependent diabetes ellitus, multiple sclerosis, Crohn's disease, Pemphigus vulgaris, autoimmune thrombocytopenic purpura, autoimmune hemolytic anemia.
An excessive Th 2 response leads to extreme sensitivity towards foreign components which should not lead to any immunological reaction, e.g. allergies and related diseases such as atopic dermatitis, asthma, occupational asthma, food allergy (e.g. cows milk allergy, apple allergy, peanut and other nut allergies, lupine allergy), allergic rhinitis (e.g. pollen allergy), dust mite allergy and other forms of hypersensitivity like systemic anaphylaxis and acute urticaria.
A relative shift towards an increased Th 2 response and/or reduced Thl response is found under circumstances of stress of any sort, which consequently results in a bias towards a Th 2 response. Such relative shift is for example observed in immunosenescence, cancer patients, chronic infections, an overload of exercise, social conflicts or high work loads, exposure to toxic components or radiation and metabolic stress leading to malnutrition, cachexia or malnutrition caused by anorexia. (Janeway (2001) Immunobiology 5th edition, Garland publishing ISBN 0-8153-3642-x; Roitt et al (2001) Immunology 6th edition, Harcourt publishing limited, ISBN-0-7234-31892).
Bifidogenic effects are held responsible for e.g. reduction and/or prevention of bacterial infection. It is known that oUgosacchandes can display bifidogenic effects.
Acid oligosaccharides have been described to have advantageous effects. WO 02/42484 describes esterified pectin hydrolysates for the treatment of infection and/or the prevention of adhesions of harmful substances to eukaryotic cells. DE 4223613 describes a process for the preparation of unsaturated uronides from pectin-like substances through anaerobic fermentation, using e.g pectate lyase. The preparation can be used for the medical treatment of heavy metal intoxication.
Also combinations of acid- and neutral oligosaccharides have been described. EP 1105002 describes a prebiotic composition comprising transgalactooligosaccharides, inulin and galacturonic acid oligosaccharides. US 6576251 describes a combination of sialyated oligosaccharide (disialolacto-N-tetraose) and galactooUgosaccharides, for the prophylaxis of symptoms connected with the adhesion of organisms such as influenza. WO 01/60378 describes mixtures of unsaturated pectin hydrolysate and neutral oUgosaccharides for the prevention of adhesion of pathogens to epitheUal surfaces. Infant formulae containing Upid, protein, saccharides, vitamin and at least one selected from di-or higher saccharide containing galactose, a derivative thereof, saccharide containing N-acetylneuraminic acid and a derivative thereof are known (EP 1332759). SUMMARY OF THE INVENTION
Until now it has been assumed that administration of (acid) oUgosaccharides provides an advantageous effect by stimulating bifidogenic flora, and preventing adhesion of pathogens to the epitheUal tissues.
The present inventors have now surprisingly found that systemic markers for the function of the immune system are influenced by the administration of (acid) oligosaccharides. This finding opens a new field of application of oUgosaccharides, particularly for diseases which at best can be treated by immune system modulation By "modulation" or "modulating" is intended an increase or decrease in a particular character, quaUty, activity, substance or response. In other words, it has surprisingly been found that acid oUgosaccharides and neutral oligosaccharides are capable of stimulating the systemic immune response.
The present inventors also surprisingly found that the different oUgosaccharides have different stimulatory effects on the immune system. It was found that administration of acid oUgosaccharides (relatively) stimulates Thl response and lowers the Th2 cytokine release (e.g. IL-10, IL-4 and IL-5). It was also found that administration of a combination of acid oUgosaccharide and neutral oUgosaccharide synergistically stimulates the immune-system, particularly by lowering the Th2 response and increasing the Thl response.
In a further aspect of the present invention it was found that oUgosaccharides can be advantageously used to restore disbalance in the Thl/Th2 responses and for the treatment and prevention of disorders which are associated with Thl/Th2 disbalance. In particular, it was surprisingly found that the administration of acid oligosaccharide, optionally combined with neutral oUgosaccharide, is able to restore Thl/Th2 disbalance and/or maintain a favorable Thl/Th2 balance. It was also found that acid oUgosaccharide, preferably in combination with the neutral oligosaccharide is capable of stimulating Thl response. The present inventors also beUeve that the administration of acid- and neutral oUgosaccharides stimulates Th3, i.e. enhances the regulatory T cell activity. It is perceived that the stimulation of Thl response is achieved in part by inhibiting Th2 response.
Hence, the present invention provides a method for
- modulating the immune system;
- stimulating the development of the immune system, particularly in humans of the age between 0-1 year;
- enhancing systemic immune response; - treatment and/or prevention of Thl/Th2 disbalance; and/or
- treatment and or prevention of diseases which at best can be treated by immune- system modulation; wherein the method comprises the administration of acid oUgosaccharide, preferably acid- and neutral oligosaccharide, more preferably acid oligosaccharide and two chemically distinct neutral oUgosaccharides.
In other words it can thus be said that acid oUgosaccharide has a beneficial effect on inflammatory cytokines (Thl response). In addition the combination of acid oUgosaccharide and neutral oUgosaccharide has a beneficial effect on inflammatory cytokines (Th2 response).
DETAILED DESCRIPTION
The present invention relates to a method for the treatment and or prevention of an immune system related disorder in a mammal, said method comprising administering to said mammal a composition comprising a therapeutically effective amount of acid oUgosaccharide and neutral oUgosaccharide, i.e. the use of acid oUgosaccharide and neutral oUgosaccharide in the manufacture of a composition for the treatment and/or prevention of an immune system related disorder in a mammal.
In a further aspect, the present invention relates to the use of acid oUgosaccharide and neutral oUgosaccharide in the manufacture of a composition for enhancing the immune response in a mammal and/or a method for modulating the immune system.
In yet a further aspect, the present invention relates to a food composition comprising between 5 and 50 en% Upid, between 10 and 60 en% protein, between 15 and 90 en% carbohydrate, and preferably a caloric density between 0.5 and 2 kcal/ml, acid oUgosaccharide and neutral oUgosaccharide, wherein said acid oUgosaccharide comprises at least one terminal uronic acid unit; and said neutral oUgosaccharide is selected from the group consisting of cellobiose, cellodextrin, B-cyclodextrin, indigestible dextrin, gentiooligosaccharide, glucooUgosaccharide, isomaltooligosaccharide, isomaltose, isomaltriose, panose, leucrose, palatinose, theanderose, D-agatose, D-Z xø-hexulose, lactosucrose, α- galactooUgosaccharide, β-galactooligosaccharide, transgalactooligosaccharide, lactulose, 4'-galatosyllactose, synthetic galactooligosaccharide, fructans - Levan-type, fructans - InuUn-type, 1 f-β-fructofuranosylnystose, xylooUgosaccharide, lafinose, lactosucrose and arabinooUgosaccharide.
In a further aspect the present invention relates to a method for the treatment and/or prevention of an immune system related disorder selected from autoimmune disorders, hereditary or conditional induced immunodeficiency, support for vaccinations, allergy Type 1, allergy Type 2 and allergy Type 3, said method comprising administering to said mammal a composition comprising a therapeutically effective amount of acid oUgosaccharide.
Some diseases that are thought to be caused/mediated in substantial part by Th2 immune response, IL-4/IL-5 cytokine induction, and/or eosinophiUa (and accordingly responsive to treatment according to the present invention) include asthma, allergic rhinitis, systemic lupus erythematosis, Ommen's syndrome (hypereosinophiUa syndrome). These are examples of non- viral and non-tumor, Th2 mediated diseases for which effective treatment with the method of the present invention clearly could not have been predicted. Particularly preferred methods of the present invention are for the treatment of diseases associated with eosinophiUa, such as asthma and allergic rhinitis.
A therapeutically effective amount for a particular disorder can be routinely determined by one of skill in the art via dose-finding studies.
Immune system related disorder
It has now been found that the administration of acid oUgosaccharide, preferably combined with neutral oUgosaccharide provides beneficial systemic effects to the subject. Systemic means affecting the entire body as a result of the (systemic) circulation of the blood and/or lymph.
In one aspect, the present invention provides a method for modulating and/or enhancing the immune system, said method comprising the administration of acid- and neutral oUgosaccharides. This method can be suitably used in a method for balancing the Thl/ Th2 response, in particular by simulating the Thl response. Hence, compositions containing the present oUgosaccharide(s) which are advertised to e.g. simulate maturation of the immune system, enhance the resistance to pathogens by enhancing the immune system and or support the immune system are part of the present invention. In a further aspect, the present invention provides a method for the treatment and/or prevention of an immune system related disorder, said method comprising administering to said mammal a composition comprising a therapeutically effective amount of acid oUgosaccharide.
In a further aspect, the present invention provides a method of enhancing the immune response in a mammal said method comprising administering to the mammal a composition comprising acid oUgosaccharide, optionally combined with neutral oUgosaccharide. It was particularly surprising that the enteral administration of the present oUgosaccharides provides the beneficial systemic effects. Hence, the present method preferably comprises the enteral, even more preferably the oral administration of acid oUgosaccharide or acid- and neutral oUgosaccharide.
In a further embodiment, the method of the invention relates to the administration of oUgosaccharides to infants, preferably humans in the age of 0 to 6 years, preferably in the age of between 0 and 1 year. As this group has a particular disbalance in the Thl/Th2 ratio (the Th2 prevails in many cases), the present method can be suitably used to restore this disbalance in this population. Administration of the acid oUgosaccharide, preferably combined with the neutral oUgosaccharide is also beUeved to improve maturation of the (gastro)intestinal tract of the newboms, making the present method and composition particularly suitable for administration to pre-term infants. In a preferred embodiment the present method relates to the stimulation of the maturation of the immune system in human subjects between the age of 0-6 year, preferably between 0 and 1 year.
Further preferred compositional features such as protein, carbohydrate, Upid, osmolality, viscosity and caloric density of a composition which can be suitably used in this method are described below.
The immune system related disorder is preferably selected from autoimmune disorders, hereditary or conditional induced immunodeficiency, support for vaccinations, allergy Type 1, allergy Type 2, allergy Type 3 and allergy Type 4.
Autoimmune disorders which can suitably be treated include systemic lupus erythematosus, chronic glomerulonephritis, polyarteritis nodosa, poststreotococcal acute glomerulonephritis, Graves' disease, myasthenia gravis, insuUne resistant diabetes, hashimoto's thyroiditis, haemolytic anaemia, pernicious anaemia, Goodpasture's syndrome, pemphigus vulgaris, autoimmune thrombocytopenia pupura, acute rheumatic fever, mixed essential cryoglobulinemia, autoimmune preniciopus anemia, autoimmune Addison's disease, VitiUgio, hypoglycemia, neonatal lupus rash, IDDM (insuUn dependent diabetes melUtus), rheumatoid arthritis, multiple sclerosis, psoriasis, scleroderma, Crohn's disease, IBD (inflammatory bowel disease), neuropathy, preferably insuUne resistant diabetes
Conditions of hereditary or conditional induced immunodeficiency which can suitably be treated include immunosenescence, autism, malnutrition caused by chronic diseases, such as cancer, COPD (chronic obstructive pulmonary disease), AIDS, arthritis, diabetes, anorexia, cachexia, dysphagea, kidney failure, radiation, patients suffering from chronic ulcerations and stress in more detail stress after social stress, chronic infection or cigarette smoke, air pollution, radiation, chemotherapy.
Because stimulation of the immune system is of particular importance in subjects suffering from Acquired Immunodeficiency Syndrome (AIDS) and/or Human Immunodeficiency Virus (HIV) Infection, in a preferred embodiment the present invention particularly provides a method for the treatment and/or prevention AIDS and/or HIV infection, said method comprising the enteral administration of the present acid oUgosaccharides, preferably in combination with the present neutral oUgosaccharides. The present invention also provides a method for the treatment and/or prevention of diarrhea in subjects suffering from ADDS and/or HIV infection, said method comprising enterally administering the present acid oUgosaccharides, preferably in combination with the present neutral oUgosaccharides. The present (acid) oUgosaccharide is preferably provided to the subject suffering from AIDS and/or HTV infection in a nutritional matrix, i.e. a composition comprising fat, protein and carbohydrate.
Allergies which can suitably be treated include Type 1 allergies; atopy, asthma, hay fever, eczema, food allergy, drug allergy. Type 2 allergies; haemolytic disease of new borns, autoimmune haemolytic anaemia, ankylosing spondyUtis, acute anterior uveitis. Type 3 allergies; arthus reaction, serum sickness. Type 4 allergies: delayed type hypersensitivity, contact sensitivity, ceUac disease. It was also found that the present method can suitably be used to support vaccination processes, e.g. enhance the effects of a vaccination process. These are included in the term immune system related disorders. The acid oUgosaccharides, preferably combined with the neutral oUgosaccharides, are preferably (orally) administered before, during and/or after vaccination. Particularly the effects of vaccinations for diptheria-tetanus- pertussis, poUo vaccine, measles/mumps/rubella, pneumococcal conjugate, haemophilus B conjugate, hepatitis B, hepatitis A, varicella, influenza can suitably be enhanced.
Preferably the present method relates to the treatment and or prevention of malnutrition, atopy, asthma or COPD.
The present invention also relates to the use of acid oUgosaccharides in the manufacture of a composition for the treatment and/or prevention of an immune system related disorder selected from autoimmune disorders, hereditary or conditional induced immunodeficiency (preferably not AIDS), support for vaccinations, allergy Type 1, allergy Type 2 and allergy Type 3.
Acid oligosaccharides
The term acid oUgosaccharide refers to oUgosaccharides comprising at least one acidic group selected from the group consisting of N-acetylneuraminic acid, N- glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group. The acid oUgosaccharide preferably is a polyhexose. Preferably, at least one of the aforementioned acid groups is situated at the terminal hexose unit of the acid oUgosaccharide. Preferably the acid oUgosaccharide has the structure as depicted in Fig.l, wherein the terminal hexose (left) preferably comprises a double bond. Preferably the acid oUgosaccharide contains a carboxylic acid at the terminal hexose unit, wherein said carboxyUc acid group may be free or esterified. Methods for the manufacture of esterified pectin hydrolysates that can be suitably used in the present method and composition are provided in WO 01/60378 and/or WO02/42484, which are hereby incorporated by reference. The hexose units other than the terminal hexose unit(s) are preferably uronic acid units, even more preferably galacturonic acid units. The carboxyUc acid groups on these units may be free or (partly) esterified, and preferably at least 10% is methylated (see below).
Fig.l. Polymeric acid oUgosaccharide
Figure imgf000011_0001
wherein: R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy; and at least one selected from the group consisting of R2, R3, R4 and R5 represents N- acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxyUc acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, R4 and R5 representing hydroxy and/or hydrogen. Preferably one selected from the group consisting of R2, R3, R4 and R5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxyUc acid, sulfuric acid group or phosphoric acid group, and the remaining represent hydroxy and/or hydrogen. Even more preferably one selected from the group consisting of R , R , R4 and R5 represents free or esterified carboxyUc acid and the remaining of R2, R3, R4 and R5 representing hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit. Suitably n is an integer between 1-5000. Preferably the hexose unit(s) is an uronic acid unit. Most preferably Ri, R2 and R3 represent hydroxy, R4 represent hydrogen, R5 represents carboxyUc acid, n is any number between 1 and 250, preferably between 1 and 10 and the hexose unit is galacturonic acid. The detection, measurement and analyses of the preferred acid oUgosaccharides as used in the present method are given in appUcant's earlier patent application relating to acid oUgosaccharides, i.e. WO 0/160378, which is hereby incorporated by reference.
Preferably, the acid oUgosaccharide has one, preferably two, terminal uronic acid units, which may be free or esterified. Preferably the terminal uronic acid unit is selected from the group consisting of galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and alturonic acid. These units may be free or esterified. In an even more preferred embodiment, the terminal hexose unit has a double bond, which is preferably situated between the C4 and C5 position of the terminal hexose unit. Preferably one of the terminal hexose units comprises the double bond. The terminal hexose (e.g. uronic acid) preferably has a structure according to Fig.2. Fig. 2: Preferred terminal hexose acid group
Figure imgf000012_0001
wherein; R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy (see above); and at least one selected from the group consisting of R2, R3, R4 and R5 represents N- acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxyUc acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, R/t and R5 representing hydroxy and/or hydrogen. Preferably one selected from the group consisting of R2, R3, t and R5 represents N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxyUc acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, Rt and R5 represent hydroxy and/or hydrogen. Even more preferably one selected from the group consisting of R2, R3, R4 and R5 represents free or esterified carboxyUc acid and the remaining of R2, R3, R4 and R5 represent hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit. Suitably n is an integer between 1-5000 representing the number of hexose units said hexose units preferably being uronic acid, even more preferably being galacturonic acid units. The carboxyUc acid groups on these units may be free or (partly) esterified, and are preferably at least partly methylated. Most preferably, R2 and R3 represent hydroxy, R4 represent hydrogen and R5 represents free or esterified carboxylic acid.
In a further embodiment, a mixture of acid oligosaccharides is used, which have a different DP and/or comprise both unsaturated and saturated terminal hexose unit.
Preferably at least 5%, more preferably at least 10%, even more preferably at least 25% of the terminal hexose units of the acid oUgosaccharide unsaturated hexose unit (see e.g.
Fig.2). As each individual acid oligosaccharide preferably comprises only one unsaturated terminal hexose unit, preferably no more than 50% of the terminal hexose units is an unsaturated hexose unit (i.e. comprises a double bond).
A mixture of acid oUgosaccharides preferably contains between 2 and 50% unsaturated hexose units based on the total amount of hexose units, preferably between 10 and 40%.
The acid oligosaccharide as used in the present method has a degree of polymerisation (DP) between 1 and 5000, preferably between 1 and 1000, more preferably between 2 and 250, even more preferably between 2 and 50, most preferably between 2 and 10. If a mixture of acid oUgosaccharides with different degrees of polymerisation is used, the average DP of the acid oUgosaccharide mixture is preferably between 2 and 1000, more preferably between 3 and 250, even more preferably between 3 and 50. See also Fig.l, wherein the sum of "n" and the terminal unit (i.e. n+1) represents the degree of polymerisation. It was found that a lower DP of the oUgosaccharides improves the palatabiUty and results in a reduced viscosity product if the acid oUgosaccharide is administered in Uquid form. The acid oUgosaccharide may be a homogeneous or heterogeneous carbohydrate.
The acid oUgosaccharides used in the invention are preferably prepared from pectin, pectate, alginate, chondroitine, hyaluronic acids, heparine, heparane, bacterial carbohydrates, sialoglycans, fucoidan, fucooUgosaccharides or carrageenan, preferably from pectin or alginate. The acid oUgosaccharides may be prepared by the methods described in WO 01/60378, which is hereby incorporated by reference.
Alginates are Unear unbranched polymers containing β-(l-> 4)-Unked D-mannuronic acid and α-(l- 4)-tinked L-guluronic acid residues with a wide range of average molecular weights (100 - 100000 residues). Suitable sources of alginate include seaweeds and bacterial alginates.
Pectin is divided into two main categories: high methoxylated pectin, which is characterised by a degree of methoxylation above 50% and low methoxylated pectin having a degree of methoxylation below 50%. As used herein, "degree of methoxylation" (also referred to as DE or "degree of esterification") is intended to mean the extent to which free carboxyUc acid groups contained in the polygalacturonic acid chain have been esterified (e.g. by methylation). The present acid oUgosaccharide is preferably prepared from high methoxylated pectin.
The acid oUgosaccharides are preferably characterised by a degree of methoxylation above 20%, preferably above 50 % even more preferably above 70%. Preferably the acid oUgosaccharides have a degree of methylation above 20%, preferably above 50 % even more preferably above 70%.
The acid oUgosaccharide is preferably administered in an amount of between 10 mg and 100 gram per day, preferably between 100 mg and 50 grams per day, even more between 0.5 and 20 gram per day. Neutral oligosaccharides
The term neutral oUgosaccharides as used in the present invention refers to saccharides which have a degree of polymerisation of monose units exceeding 2, more preferably exceeding 3, even more preferably exceeding 4, most preferably exceeding 10, which are not or only partially digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach) but which are fermented by the human intestinal flora and preferably lack acidic groups. The neutral oligosaccharide is structurally (chemically) different from the acid oligosaccharide. The term neutral oUgosaccharides as used in the present invention preferably refers to saccharides which have a degree of polymerisation of the oligosaccharide below 60 monose units, preferably below 40, even more preferably below 20, most preferably below 10.
The term monose units refers to units having a closed ring structure, preferably hexose, e.g. the pyranose or furanose forms. The neutral oUgosaccharide preferably comprises at least 90%, more preferably at least 95% monose units selected from the group consisting of mannose, arabinose, fructose, fucose, rhamnose, galactose, β-D-galactopyranose, ribose, glucose, xylose and derivatives thereof, calculated on the total number of monose units contained therein.
Suitable neural oUgosaccharides are preferably fermented by the gut flora. Preferably the oUgosaccharide is selected from the group consisting of: cellobiose (4-O-β-D-glucopyranosyl-D-glucose), cellodextrins ((4-O-β-D- glucopyranosyl)n-D-glucose), B-cyclodextrins (CycUc molecules of α-l-4-linked D- glucose; α-cyclodextrin-hexamer, β-cyclodextrin-heptamer and γ-cyclodextrin-octamer), indigestible dextrin , gentiooUgosaccharides (mixture of β-1-6 linked glucose residues, some 1-4 linkages), glucooUgosaccharides (mixture of α-D-glucose), isomaltooUgosaccharides (Unear α-1-6 Unked glucose residues with some 1-4 Unkages), isomaltose (6-O-α-D-glucopyranosyl-D-glucose); isomaltriose (6-O-α-D- glucopyranosyl-(l-6)-α-D-glucopyranosyl-D-glucose), panose (6-O-α-D- glucopyranosyl-(l-6)-α-D-glucopyranosyl-(l-4)-D-glucose), leucrose (5-O-α-D- glucopyranosyl-D-fructopyranoside), palatinose or isomaltulose (6-O-α-D- glucopyranosyl-D-fructose), theanderose (O-α-D-glucopyranosyl-(l-6)-O-α-D- glucopyranosyl-(l-2)-B-D-fructofuranoside), D-agatose, D-/yxø-hexulose, lactosucrose (O-β-D-galactopyranosyl-( 1 -4)-O-α-D-glucopyranosyl-( 1 -2)-β~D-fructofuranoside), α- galactooUgosaccharides including raffinose, stachyose and other soy oUgosaccharides (O- α-D-galactopyranosyl-(l-6)-α-D-glucopyranosyl-β-D-fructofuranoside), β- galactooUgosaccharides or transgalacto-oUgosaccharides (β-D-galactopyranosyl-(l-6)-[β- D-glucopyranosyl]n-(l-4) α-D glucose), lactulose (4-O-β-D-galactopyranosyl-D- fructose), 4'-galatosyllactose (O-D-galactopyranosyl-(l-4)-O-β-D-glucopyranosyl~(l-4)- D-glucopyranose), synthetic galactooUgosaccharide (neogalactobiose, isogalactobiose, galsucrose, isolactosel, II and III), fructans - Levan-type (β-D-(2->6)-fructofuranosyl)n -D-glucopyranoside), fructans - Inulin-type(β-D-((2- )-fructofuranosyl)n α-D- glucopyranoside), 1 f-β-fructofuranosylnystose
Figure imgf000016_0001
B-D- fructofuranoside), xylooligosaccharides (B-D-((l->4)-xylose)n, lafinose, lactosucrose and arabinooUgosaccharides.
According to a further preferred embodiment the neutral oligosaccharide is selected from the group consisting of fructans, fructooUgosaccharides, indigestible dextrins galactooUgosaccharides (including transgalactooUgosaccharides), xylooligosaccharides, arabinooUgosaccharides, glucooUgosaccharides, mannooligosaccharides, fucooUgosaccharides and mixtures thereof. Most preferably the neutral oUgosaccharide is selected from the group consisting of fructooUgosacchararides, galactooUgosaccharides and transgalactooUgosaccharides.
Suitable oUgosaccharides and their production methods are further described in Laere K.J.M. (Laere, K.J.M., Degradation of structurally different non-digestible oUgosaccharides by intestinal bacteria: glycosylhydrolases of Bi. adolescentis. PhD-thesis (2000), Wageningen Agricultural University, Wageningen, The Netherlands) the entire content of which is hereby incorporated by reference. TransgalactooUgosaccharides (TOS) are for example sold under the trademark Vivinal™ (Borculo Domo Ingredients, Netherlands).
Indigestible dextrin, which may be produced by pyrolysis of corn starch, comprises α(l-^4) and α(l->6) glucosidic bonds, as are present in the native starch, and contains l->2 and l- 3 Unkages and levoglucosan. Due to these structural characteristics, indigestible dextrin contains well-developed, branched particles that are partially hydrolysed by human digestive enzymes.
Numerous other commercial sources of indigestible oUgosaccharides are readily available and known to skilled person. For example, transgalactooUgosaccharide is available from Yakult Honsha Co., Tokyo, Japan. Soybean oUgosaccharide is available from Calpis Corporation distributed by Ajinomoto U.S.A. Inc., Teaneck, NJ.
In a further preferred embodiment the present method comprises the administration of 2 chemically distinct oUgosaccharides. It was found that the administration of acid oUgosaccharides combined with two chemically distinct neutral oUgosaccharides provides an optimal effect. Preferably the present method comprises the administration of an
- acid oUgosaccharides (see above); - galactose based neutral oUgosaccharide (>50 % of the monose units are galactose), preferably selected from the group consisting of galactooUgosaccharide and transgalactooUgosaccharide; and
- fructose and/or glucose based neutral oligosaccharides (>50% of the monose units are fructose and/or glucose, preferably fructose), preferably inuUn, fructan and/or fructooUgosaccharide, most preferably long chain fructooUgosaccharide (average DP between 10 and 60). This composition is particularly suited for administration to infants in the age between 0- 1 year. In a further embodiment, the present method comprises the administration of 2 structurally (chemically) distinct oUgosaccharides, wherein two structurally (chemically) distinct oligosaccharides are differentiated by their type of glycosidic Unkages.
Preferably the method comprises the administration of two chemically distinct neutral oUgosaccharides, said chemically distinct oUgosaccharides having a different DP and/or different average DP, preferably different average DP. In another embodiment administering chemically distinct neutral oUgosaccharides with different average DP, provides an even more optimal immune-modulating effect. Preferably galactose based neutral oUgosaccharide has an average DP between 2 and 10, and fructose and/or glucose based neutral oUgosaccharides have an average DP between 10 and 60.
The neutral oligosaccharide is preferably administered in an amount of between 10 mg and 100 gram per day, preferably between 100 mg and 50 grams per day, even more preferably between 0.5 and 20 gram per day.
Synergistic effect acid and neutral oligosaccharides
The acid- and neutral oUgosaccharides were found to have a synergistic immune stimulatory effect. Hence, preferably the present method comprises the administration of a therapeutically effective amount of acid oUgosaccharides and neutral oUgosaccharides.
The mixture of acid- and neutral oUgosaccharides is preferably administered in an amount of between 10 mg and 100 gram per day, preferably between 100 mg and 25 grams per day, even more preferably between 0.5 and 20 gram per day.
A preferred combination of acid oUgosaccharides and neutral oligosaccharides comprises the acid oUgosaccharides of Fig.2, wherein
R represents hydrogen, hydroxy or acid group, preferably hydroxy ; and one selected from the group consisting of R2, R3, 1^ and R5 represents free or esterified carboxyUc acid and the remaining of R2, R3, R and R5 represent hydroxy and/or hydrogen; and galactooUgosaccharide and/or transgalactooUgosaccharide. Preferably the acid and neutral oligosaccharides are administered in a weight ratio of between 0.01:1 and 1:0.01, preferably in a weight ratio of between 0.1:1 and 1: 0.1.
LCPUFA
In a preferred embodiment, the present method further comprises the administration of long-chain polyunsaturated acid (LCPUFA). As it is believed that these act on the immune system via a mechanism different from the acid oUgosaccharides or neutral oUgosaccharides, the oUgosaccharides combined with the LCPUFA is deemed to act synergistically. The present method preferably comprises the administration of between 0.1 and 100 g LCPUFA per day, more preferably between 1 and 25 grams LCPUFA per day.
Foods It was found that the acid oUgosaccharides, and particularly the synergistic mixture of acid and neutral oUgosaccharides can be advantageously appUed in food, such as baby food and clinical food. Such food preferably comprises Upid, protein and carbohydrate and is preferably administered in Uquid form. The term "Uquid food" as used in the present invention includes dry food (e.g. powders) which are accompanied with instructions as to admix said dry food mixture with a suitable Uquid (e.g. water).
Hence, the present invention also relates to a nutritional composition which preferably comprising between 5 and 50 en% Upid, between 10 and 60 en% protein, between 15 and 90 en% carbohydrate and the present acid oUgosaccharides, preferably in combination with the neutral oUgosaccharides. Preferably the present nutritional composition preferably contains between 10 and 30 en% Upid, between 15 and 40 en% protein and between 25 and 75 en% carbohydrate (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation).
Such food preferably is in Uquid form and has a Umited viscosity. It was found that the foods containing the acid oUgosaccharides, optionally combined with the neutral oUgosaccharides, provides a Uquid nutrition with sufficiently low viscosity so it can be appUed as e.g. Uquid baby foods and Uquid cUnical food which can be fed through a tube or a straw, while retaining the low viscosity. In a preferred embodiment, the present composition has a viscosity below 600 mPas, preferably below 250 mPas, more preferably below 50 mPas, most preferably below 25 mPas at a shear rate of 100s"1 at 20°C. Whenever the term viscosity used in the present document, this refers to the physical parameter which is determined according to the following method: The viscosity may be determined using a Carri-Med CSL rheometer. The used geometry is of conical shape (6 cm 2 deg acrytic cone) and the gap between plate and geometry is set on 55 μm. A linear continuous ramp shear rate is used from 0 to 150 s"1 in 20 seconds.
Preferably vegetable Upids are used. The vegetable Upid is preferably at least one selected from the group consisting of soy oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil and lecithins. Animal fats such as milk fats may also be added if desired.
The proteins used in the nutritional preparation are preferably selected from the group of non-human animal proteins (such as milk proteins, meat proteins and egg proteins), vegetable proteins (such as soy protein, wheat protein, rice protein, and pea protein), free amino acids and mixtures thereof. Cow milk proteins such as casein and whey proteins are particularly preferred.
A source of digestible carbohydrate may be added to the nutritional formula. It preferably provides about 40% to about 80% of the energy of the nutritional composition. Any suitable (source of) carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup soUds, and maltodextrins, and mixtures thereof.
The present composition is preferably substantially free of viable bifinogenic bacteria.
Stool irregularities (e.g. hard stools, insufficient stool volume, diarrhoea) is a major problem in many babies and ill subjects that receive Uquid foods. It was found that stool problems may be reduced by administering the present oUgosaccharides in liquid food which have an osmolaUty between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg.
In view of the above, it is also important that the liquid food does not have an excessive caloric density, however still provides sufficient calories to feed the subject. Hence, the liquid food preferably has a caloric density between 0.1 and 2.5 kcal/ml, even more preferably a caloric density of between 0.5 and 1.5 kcal/ml.
Infant formula
It was found that the present composition can be advantageously applied for infant formula. Such infant formula preferably comprises Upid, protein and carbohydrate and is preferably administered in Uquid form. The term "liquid food" as used in the present invention includes dry food (e.g. powders) which are accompanied with instructions as to admix said dry food mixture with a suitable Uquid (e.g. water).
Hence, the present invention also relates to an infant formula which preferably comprises between 5 and 60 en% Upid, between 5 and 40 en% protein, between 15 and 90 en% carbohydrate and the present combination of oligosaccharides and LC-PUFA's. Preferably the present infant formula contains between 30 and 60 en% Upid, between 6 and 15 en% protein and between 25 and 75 en% carbohydrate (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation).
Preferably a combination of vegetable Upids and at least one oil selected from the group consisting of fish oil and omega-3 containing vegetable, algae or bacterial oil is used.
The proteins used in the nutritional preparation are preferably selected from the group of non-human animal proteins (such as milk proteins, meat proteins and egg proteins), vegetable proteins (such as soy protein, wheat protein, rice protein, and pea protein), free amino acids and mixtures thereof. Cow milk derived nitrogen source, particularly cow milk protein proteins such as casein and whey proteins are particularly preferred. A source of digestible carbohydrate may be added to the nutritional formula. It preferably provides about 40% to about 80% of the energy of the nutritional composition. Any suitable (source of) carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup soUds, and maltodextrins, and mixtures thereof.
According to a particularly preferred embodiment, the present infant formula contains 7 to 12 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat. As this composition is particularly suitably used to reduce the allergic reaction in an infant, the protein of the infant formula is preferably selected from the group consisting of hydrolyzed milk protein (e.g. hydrolyzed casein or hydrolyzed whey protein), vegetable protein and/or amino acids. The use of these proteins further reduced the allergic reactions of the infant.
Stool irregularities (e.g. hard stools, insufficient stool volume, diarrhea) is a major problem in many babies that receive Uquid foods. It was found that stool problems (e.g. diarrhea) may be reduced by administering the present oligosaccharides in liquid food which have an osmolaUty between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg.
In a particularly preferred embodiment, the present invention also provides a composition which is particularly suitable for use in the present method. This composition has a high similarity with natural human milk, both in functionaUty and molecular structure. Hence, the composition is particularly suitable as an infant formula. The present composition contains fat, carbohydrate, protein; and between 0.5 and 1 gram soluble indigestible oUgosaccharides per 100 ml Uquid product, preferably between 0.7 and 0.9 gram/100 ml. Furthermore the composition contains, per 100 ml Uquid product, between 0.4 and 0.7 gram transgalactooUgosaccharides (indigestible [galactose]n-glucose comprising β-Unked saccharides; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, ...., 59 ,60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10); and between 0.01 and 0.1 gram inulin (indigestible polysaccharide carbohydrate comprising a chain of at least 10 β- linked fructose units); and between 0.04 and 0.3 gram acid oligosaccharides as depicted in Figure 2. The present Uquid product can be suitably prepared by a consumer from a powdered product. The present Uquid product preferably contains the ingredients and has the characteristics as described herein above and below and can be favorably used in the methods described herein.
OUgosacchandes
The acid oUgosaccharide is preferably included in the present composition according to the invention in an amount exceeding 0.1 wt.%, preferably exceeding 0.2 wt.%, more preferably exceeding 0.5 wt.% and even more preferably exceeding 1 wt.% based on the total dry weight of the composition. Although the administration of considerable amounts of oUgosaccharides will generally not lead to undesirable side effects, the present composition preferably has an oUgosaccharide content below 20 wt.%, more preferably below 10 wt.% even more preferably below 5 wt.%.
The neutral oUgosaccharide is preferably included in the present composition according to the invention in an amount exceeding 0.1 wt.%, preferably exceeding 0.2 wt.%, more preferably exceeding 0.5 wt.% and even more preferably exceeding 1 wt.% based on the total dry weight of the composition. Although the administration of considerable amounts of oUgosaccharides will generally not lead to undesirable side effects, the present composition preferably has an oUgosaccharide content below 20 wt.%, more preferably below 10 wt.% even more preferably below 5 wt.%.
The present composition was found to synergistically stimulate the immune system. Hence, the present composition can be suitably used in a method for the treatment and/or prevention of infection, said method comprising orally administering to a human, preferably an infant, the present composition. By stimulating the immune system and by promoting a healthy intestinal flora, the present composition also has a systemic anti- infective effect. Hence, the present acid oUgosaccharides, preferably combined with the present neutral oUgosaccharides can be advantageously used for the treatment and/or prevention of intestinal infections and/or respiratory tract infections. In a further preferred embodiment the oUgosaccharide(s) are orally administered in a food matrix as described above.
Because stimulation of the immune system is of particular importance in subjects suffering from cancer, in particular those patients that are or have been subjected to chemotherapy, radiation and those patients that are cachectic (as typically occurs in the terminal phase of cancer), the present invention provides a method for the treatment of these subjects, said method comprising the enteral administration of the present acid oligosaccharides, preferably in combination with the present neutral oligosaccharides. The present (acid) oligosaccharide is preferably provided to these subjects in a nutritional matrix, i.e. a composition comprising fat, protein and carbohydrate.
EXAMPLES
Example 1:
Experimental setup
The effect of diets comprising acid oUgosaccharides, optionally combined with neutral oUgosaccharides were tested on the delayed-type hypersensitivity (DTH) response, which is a parameter for Thl immunological response and is determined by measuring the increase in ear swelUng after local antigen challenge.
Acid oUgosaccharides (AcOl) used, with an average DP between 2 and 10, were obtained by the method described in WO 02/42484 (see example 1) . Diets containing 1 wt.%, 2.5 wt.%, 5 wt.% and 10% wt.% AcOl based on total weight of the diet were tested. Neutral oUgosaccharide mixture (GF) containing galactooUgosaccharides (GOS) (Vivinal-GOS™ (Borculo Domo Ingredients, Netherlands) and fructooUgosaccharides (FOS) (Raftiline HP™, Orafti, Tienen, Belgium) were used in a weight ratio GOS:FOS of 9:1. Diets containing 1, 2.5 and 5 wt.% GF based on total weight of the diet were tested. The effects of a combination of acid and neutral oUgosaccharides (GF and AcOl) was tested in a diet containing 1 wt.% GF and 1 wt.% AcOl based on total weight of the diet. All data is presented as percentages relative to control values, i.e. the relative values of the oUgosaccharide supplemented group compared to the group receiving the control diet (without oUgosaccharides).
Animals and diets
Female, 6 weeks old C57B1/6 mice (Harlan Nederland BV, Horst, the Netherlands) were group-housed under a regular 12 hours Ught/dark regime. Group size was 10 animals per group and 3 animals in the negative control groups. The animals were given semi- synthetic diets (Research Diet Services, Wijk bij Duurstede, the Netherlands). Control diets were made to the AIN93G specifications (Reeves et al (1993) Development and Testing of the AIN93 purified diets for rodents: results on growth kidney calcification and bone mineralisation in rats and mice. J Nutrition 123(11): 1923-31), oUgosaccharide supplemented diets were based on these specifications. Carbohydrate content of the supplemented diets were kept constant by the exchange of total carbohydrates for the oUgosaccharides on a weight basis. The separate carbohydrate components were substituted respective to their normal ratio in the diet. The carbohydrates in the normal diet consist of cornstarch (40% of total weight), dextrinized cornstarch (13.2%), sucrose (10%) and cellulose (5%).
Vaccination protocol
Vaccinations were started after a period of two to four weeks of adaptation to the new housing and diets. At day 0, a blood sample was collected prior to vaccination. At day 1, the first vaccination was administered subcutaneously. After three weeks, a blood sample was collected (day 21) and a booster vaccination was given (day 22). Nine days after booster injection (day 31), basal ear thickness was measured with a Digimatic outside micrometer (Mitutoyo, Veenendaal, the Netherlands) and a delayed-type hypersensitivity (DTH) response was induced by injecting antigen solution i.e. (intracutaneous) in the mouse ear pinnae. 24 h therafter (day 32), the DTH response was measured, a bloodsample was taken and the mice were sacrificed. Spleens were isolated and prepared for ex-vivo restimulations. The vaccinations consisted of a 100 μl i.e. (intracutaneous) injection of a 1:1 mix of antigen solution and Stimune adjuvant (Specol, Cedi-diagnostics BV, Lelystad, the Netherlands). The antigen solution was a 1:100 dilution of Influvac 2002/2003 (Solvay Pharmaceuticals, Weesp, the Netherlands) in PBS . Influvac is a trivalent protein vaccine, containing 3x30 μg/ml haemagglutinin of three different influenza strains.
For the DTH responses, mice were i.e. injected with 25 μl dialysed Influvac in both ears as a DTH challenge.
Cell cultures Splenocytes were isolated from the spleens using fine-mesh cell strainers (Becton Dickinson, Erembodegem, Belgium). Red blood cells were lysed by 5 minutes incubation on ice. After washing with culture medium without phenol red, cells were counted (Coulter Counter, Beckman Coulter, the Netherlands) and kept on ice. Cultures were set up using 0.1 μg/ml dialysed Influvac as a stimulus. Cells were seeded in 96-well culture plates at 1*106 cells per well. The culture medium consisted of RPMI- 1640 with HEPES buffer and 2 mM L-Glutamine (Invitrogen, Merelbeke, Belgium) with 10% fetal calf serum (FCS). Cultures were incubated for 5 days at 37°C at 5% CO2. Thereafter supernatants were harvested and frozen at -80°C until analysis. Cell proliferation was measured in parallel cultures by 3H-thymidine incorporation, which was added to the cultures for the last 18 hours at 0.4 μCu/well. After 5 days, the cells were harvested using a Filtermate harvester (Perkin Elmer, Zaventem, Belgium) and counted on a Micro-Beta counter (Perkin Elmer, Zaventem, Belgium). Radioactive decay was measured for 1 minute per well and the counts per minute (cpm) were recorded as a measure for proUferation speed.
Cytokines were analysed in supernatants of Influvac stimulated cultures. IL-2, IL-5, IL-
10 and IFN-gamma were measured using the Bio-Plex system with a custom mixed beadset for the cytokines mentioned (Bio-Rad, Veenendaal, the Netherlands). Cytokines were measured according to the manufacturer's specifications. IL-4 was measured by ELISA using the Pharmingen OptEIA mouse IL-4 kit (Becton Dickinson, Erembodegem,
Belgium), according the manufacturer's specifications. Results DTH response acid oligosaccharides The diets containing dosages of 1 wt.%, 2.5 wt.% and 5 wt.% AcOl induced a statistically significant increase in the DTH response, showing a dose-dependent increase (see Table 1). The observed effect is indicative for the advantageous use of acid oUgosaccharides in the present method.
TABLE 1
Figure imgf000027_0001
* indicates significantly different (P<0,05) from control
DTH response acid and neutral oligosaccharides The combination of 1 wt.% GF and 1 wt.% AcOl induce a statistically significant increase in the DTH (see Table 2). As the effect is significantly higher than the DTH responses from diets containing the acid or neutral oUgosaccharides alone, these results are indicative for the synergistic effect provided by the administration of acid and neutral oUgosaccharides. The observed effect is indicative for the advantageous use of a combination of acid and neutral oligosaccharides in the present method.
Figure imgf000027_0002
* indicates significantly different (P<0,05) from control Influvac specific proliferation of acid oligosaccharides Administration of diets containing 2.5 wt% and 5 wt.% acid oUgosaccharides (AcOl) induced a significant lowering effect on the influvac specific proliferation ex vivo (see Table 3). The observed effect is indicative for the advantageous use of acid oUgosaccharides in the present method.
Influvac specific proliferation of a combination of acid and neutral oligosaccharides Administration of a combination of 1 wt.% GF and 1 wt.% AcOl induced significant lowering effects on the antigen specific proUferation (see Table 3). As the effect is significantly improved over the DTH responses from diets containing the acid or neutral oUgosaccharides alone, these results are indicative for the synergistic effect provided by the administration of acid and neutral oligosaccharides. The observed effect is indicative for the advantageous use of a combination of acid and neutral oUgosaccharides in the present method. Reduced proUferation is indicative for the reduction of Th2 response, and the Thl/Th2 balancing effect of the present method.
TABLE 3
Figure imgf000028_0001
* indicates significantly different (P<0,05) from control
Thl/Th2 balance: Cytokine profiles after administration of acid oligosaccharides Cytokine profiles were measured in the culture supernatants of the influvac specific splenocytes. Data are presented as percentage relative to values of the vaccinated control group (i.e. receiving no oligosaccharides). Compared to controls, diets containing 2.5 wt.% and 5 wt.% AcOl resulted in a decrease in the Th2-related cytokines IL-4 , IL-5 and IL-10, while the Thl -related cytokines IL-2 was increased and IFN-γ was not significantly lowered (see Table 4). These results are indicative for the Thl/Th2 balancing effect of acid oUgosaccharides and indicative for the advantageous use of acid oUgosaccharides in the present method, e.g. for the treatment and/or prevention of diseases with relatively low Thl immunity. Ηιl Th2 balance: Cytokine profiles after administration of acid and neutral oligosaccharides Compared to controls, administration of a combination of 1 wt.% GT and 1 wt.% AcOl resulted in a decrease in the Th2-related cytokines IL-4, IL-5 and IL-10, while the Thl - related cytokines IL-2 and IFN-γ were not lowered (see Table 4, wherein data are presented as percentage relative to values of the vaccinated control group (i.e. receiving no oUgosaccharides)). These results are indicative for the Thl/Th2 balancing effect of a combination of acid- and neutral oligosaccharides and indicative for the advantageous use of acid oUgosaccharides in the present method, e.g. for the treatment and/or prevention of diseases with relatively low Thl immunity. Particularly the IL-4/IFN ratio reflects the Th2/Thl balance. In other words, a lower ratio is indicative for stimulation of Thl and/or inhibition of Th2, and in any case indicative for the Thl-Th2 balancing effect of the present oUgosaccharides.
TABLE 4
Figure imgf000029_0001
* indicates significantly different (P<0,05) from control

Claims

1. Use of acid oUgosaccharide and neutral oligosaccharide in the manufacture of a composition for use in a method for the treatment and/or prevention of an immune system related disorder in a mammal, said method comprising administering to said mammal a composition comprising a therapeutically effective amount of acid oUgosaccharide and neutral oUgosaccharide.
2. Use of acid oUgosaccharide and neutral oligosaccharide in the manufacture of a composition for use in a method for enhancing the immune response in a mammal and/or a method for modulating the immune system in a mammal, said method comprising administering to the mammal a composition comprising acid oUgosaccharide and neutral oUgosaccharide.
3. Use according to claim 1, wherein the immune system related disorder is selected from the group consisting of autoimmune disorders, hereditary or conditional induced immunodeficiency, support for vaccinations, allergy Type 1, allergy Type 2, allergy Type 3 and allergy Type 4.
4. Use according to any one of the preceding claims, wherein the acid oUgosaccharide comprises at least one terminal uronic acid unit.
5. Use according to claim 4, wherein the uronic acid unit is selected from the group consisting of galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and alturonic acid.
6. Use according to any one of the preceding claims, wherein the terminal hexose unit has the following structure:
Figure imgf000031_0001
wherein;
R is selected from the group consisting of hydrogen, hydroxy or acid group; and at least one selected from the group consisting of R2, R3, R4 and R5 represent N-acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxyUc acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R , ILj and R5 represent hydroxy and/or hydrogen; and n is an integer from 1-5000.
7. Use according to claim 4, wherein the terminal uronic acid has the structure as depicted in claim 7 and wherein R represents one selected from the group consisting of hydrogen, hydroxy or acid group ; and one selected from the group consisting of R2, R3, R4 and R5 represents free or esterified carboxyUc acid; and the remaining of R2, R3, R4 and R5 represent hydroxy and/or hydrogen.
8. Use according to any one of the preceding claims, wherein the acid oUgosaccharide has a degree of polymerisation between 1 and 250, preferably between 1 and 10.
9. Use according to any one of the preceding claims, wherein the neutral oUgosaccharide is selected from the group consisting of cellobiose, cellodextrins, B- cyclodextrins, indigestible dextrin, gentiooUgosaccharides, glucooUgosaccharides, isomaltooUgosaccharides, isomaltose, isomaltriose, panose, leucrose, palatinose, theanderose, D-agatose, D-Zy;rø-hexulose, lactosucrose, α-galactooligosaccharides, β- galactooligosaccharides, transgalactooUgosaccharides, lactulose, 4'-galatosyllactose, synthetic galactooUgosaccharide, fructans - Levan-type, fructans - InuUn-type, 1 f-β- fructofuranosylnystose, xylooligosaccharide, lafinose, lactosucrose and arabinooUgosaccharides .
10. Use according to claim 9, wherein the neutral oUgosaccharide selected is from the group consisting of galactooUgosaccharide, fructooUgosaccharide and transgalactooUgosaccharide.
11. Use according to any one of the preceding claims, wherein the composition comprises two chemically distinct neutral oUgosaccharides, one selected from the group consisting of galactose based neutral oligosaccharide and one selected from the group of fructose and/or glucose based oUgosaccharide.
12. Use according to claim 11, wherein the composition comprises fructooUgosaccharide and at least one selected from transgalactootigosaccharride and galactooUgosaccharide.
13. Use according to any one of the preceding claims, wherein the method comprises the enteral administration of the composition.
14. Use according to any of the preceding claims, wherein the composition is administered to a human in the age of 0-1 year.
15. A food composition comprising between 5 and 50 en% Upid, between 10 and 60 en% protein, between 15 and 90 en% carbohydrate, acid oUgosaccharide and neutral oUgosaccharide, wherein said acid oligosaccharide comprises at least one terminal uronic acid unit, and said neutral oUgosaccharide is selected from the group consisting of cellobiose, cellodextrins, B-cyclodextrins, indigestible dextrin, gentiooUgosaccharides, glucooUgosaccharides, isomaltooUgosaccharides, isomaltose, isomaltriose, panose, leucrose, palatinose, theanderose, D-agatose, D-/yjco-hexulose, lactosucrose, α- galactooUgosaccharides, β-galactooUgosaccharides, transgalactooUgosaccharides, lactulose, 4'-galatosyllactose, synthetic galactooUgosaccharide, fructans - Levan-type, fructans - InuUn-type, 1 f-β-fructofuranosylnystose, xylooUgosaccharides, lafinose, lactosucrose and arabinooUgosaccharides.
16. Composition according to claim 14, wherein the acid oUgosaccharide has the following structure:
Figure imgf000033_0001
wherein;
R is selected from the group consisting of hydrogen, hydroxy or acid group; and at least one selected from the group consisting of R , R3, R4. and R5 represent free or esterified carboxyUc acid, and the remaining of R2, R3, * and R5 represent hydroxy and/or hydrogen; n is an integer from 1-5000; representing the number of hexose units said hexose units being uronic acid.
17. Composition according to any of claims 14 or 15, wherein the composition has a caloric density between 0.1 and 2.5 kcal/ml.
18. Composition according to any of claims 14-17, wherein the composition has a viscosity below 250 mPas at a shear rate of 100 s"1 at 20°C.
19. Liquid composition comprising fat, carbohydrate and protein and comprising, per 100 ml of the liquid composition, between 0.5 and 1 g soluble indigestible oUgosaccharides, comprising between 0.4 and 0.7 g indigestible [galactose]n-glucose comprising β-Unked saccharides; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, ...., 59 ,60; between 0.01 and 0.1 g indigestible polysaccharide carbohydrate comprising a chain of at least 10 β-Unked fructose units; and between 0.04 and 0.3 g acid oUgosaccharides said acid oUgosaccharides having the structure as defined in claim 16.
20. Use of acid oUgosaccharide in the manufacture of a composition for use in a method for the treatment and/or prevention of an immune system related disorder selected from the group consisting of autoimmune disorders, hereditary or conditional induced immunodeficiency, support for vaccinations, allergy Type 1, allergy Type 2 and allergy Type 3 in a mammal, said method comprising administering to said mammal a composition comprising a therapeutically effective amount of acid oUgosaccharide as defined in claim 22.
21. Use of acid oUgosaccharide in the manufacture of a composition for use in a method for the treatment and/or prevention of subjects suffering from cancer, in particular cancer patients that are or have been subjected to chemotherapy, radiation and cancer patients that are cachectic, said method comprising administering to said subject a composition comprising a therapeutically effective amount of acid oUgosaccharide as defined in claim 22.
22. Use of acid oUgosaccharides with the formula
Figure imgf000034_0001
wherein:
R is selected from the group consisting of hydrogen, hydroxy or acid group; and at least one selected from the group consisting of R2, R3, R and R5 represents N- acetylneuraminic acid, N-glycoloylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R2, R3, R4 and R5 representing hydroxy and/or hydrogen; and n is an integer between 1-5000.
for the manufacture of a composition for the treatment and/or prevention of AIDS and/or HIV infection.
PCT/NL2004/000750 2003-10-24 2004-10-25 Immunemodulating oligosaccharides WO2005039597A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP10186333.0A EP2305269B1 (en) 2003-10-24 2004-10-25 Immunemodulating oligosaccharides
US10/576,834 US8557794B2 (en) 2003-10-24 2004-10-25 Immunemodulating oligosaccharides
JP2006536469A JP4943853B2 (en) 2003-10-24 2004-10-25 Immunomodulatory oligosaccharides
BRPI0415699-4A BRPI0415699A (en) 2003-10-24 2004-10-25 use of acid oligosaccharide and neutral oligosaccharide, and food and liquid compositions
NZ546785A NZ546785A (en) 2003-10-24 2004-10-25 Immunemodulating oligosaccharides
EP04793675A EP1675595A2 (en) 2003-10-24 2004-10-25 Immunemodulating oligosaccharides
CN2004800312436A CN1871015B (en) 2003-10-24 2004-10-25 Immunemodulating oligosaccharides
DK06111971T DK1733730T3 (en) 2003-10-24 2004-10-25 Immunomodulatory oligosaccharides
CA2542996A CA2542996C (en) 2003-10-24 2004-10-25 Immunemodulating oligosaccharides
DK06115301T DK1721612T3 (en) 2003-10-24 2004-10-25 Immunomodulatory oligosaccharides
AU2004283628A AU2004283628B2 (en) 2003-10-24 2004-10-25 Immunemodulating oligosaccharides
AU2010235987A AU2010235987A1 (en) 2003-10-24 2010-10-22 Immunemodulating oligosaccharides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03078375.5 2003-10-24
EP03078375 2003-10-24
EP04076877 2004-06-25
EP04076877.2 2004-06-25

Publications (2)

Publication Number Publication Date
WO2005039597A2 true WO2005039597A2 (en) 2005-05-06
WO2005039597A3 WO2005039597A3 (en) 2005-07-14

Family

ID=34524733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2004/000750 WO2005039597A2 (en) 2003-10-24 2004-10-25 Immunemodulating oligosaccharides

Country Status (19)

Country Link
US (1) US8557794B2 (en)
EP (8) EP1733730B1 (en)
JP (1) JP4943853B2 (en)
CN (1) CN101987107A (en)
AT (2) ATE400278T1 (en)
AU (2) AU2004283628B2 (en)
BR (1) BRPI0415699A (en)
CA (1) CA2542996C (en)
CY (2) CY1108342T1 (en)
DE (2) DE602004020809D1 (en)
DK (2) DK1733730T3 (en)
ES (3) ES2324369T3 (en)
NZ (2) NZ546785A (en)
PL (2) PL1733730T3 (en)
PT (2) PT1733730E (en)
RU (2) RU2388478C2 (en)
SG (2) SG152270A1 (en)
SI (2) SI1733730T1 (en)
WO (1) WO2005039597A2 (en)

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1685763A1 (en) * 2004-05-17 2006-08-02 N.V. Nutricia Synergism of GOS and polyfructose
WO2006112717A2 (en) * 2005-04-21 2006-10-26 N.V. Nutricia Nutritional supplement for a category of hiv patients
WO2006112716A2 (en) * 2005-04-21 2006-10-26 N.V. Nutricia Nutritional supplement for hiv patients
EP1723951A1 (en) * 2005-04-21 2006-11-22 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
EP1733730A3 (en) * 2003-10-24 2006-12-27 N.V. Nutricia Immunemodulating oligosaccharides
EP1745705A1 (en) * 2005-07-20 2007-01-24 N.V. Nutricia Process for preparing uronic acid oligosaccharides by extrusion
WO2007046697A1 (en) * 2005-10-21 2007-04-26 N.V. Nutricia Method for treating and/or preventing infections in infants delivered via caesarean section
WO2007067053A1 (en) 2005-12-06 2007-06-14 N.V. Nutricia Composition containing oligosaccharides for the treatment / prevention of infections
WO2007069900A1 (en) 2005-12-16 2007-06-21 N.V. Nutricia Use of soluble dietary fibres against muscle wasting
WO2007090894A1 (en) * 2006-02-10 2007-08-16 Nestec S.A. Oligosaccharide mixture
WO2007114696A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
WO2008010428A1 (en) * 2006-07-19 2008-01-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Immunomodulating agent
JP2008247858A (en) * 2007-03-30 2008-10-16 Hayashibara Biochem Lab Inc Dietary composition for oral administration
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US20090297636A1 (en) * 2006-02-07 2009-12-03 Martine Sandra Alles Sensoric imprinting
CN1871015B (en) * 2003-10-24 2010-06-16 努特里奇亚有限公司 Immunemodulating oligosaccharides
WO2010095943A2 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of resveratrol or another hydroxylated stilbene for preserving cognitive functioning
WO2010104394A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
WO2010140891A2 (en) 2009-06-05 2010-12-09 N.V. Nutricia Liquid enteral nutritional composition with a low monovalent metal ion content
WO2010143961A1 (en) 2009-06-12 2010-12-16 N.V. Nutricia Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages
WO2011008087A1 (en) * 2009-07-15 2011-01-20 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
WO2011008086A1 (en) 2009-07-15 2011-01-20 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
WO2011078677A2 (en) 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
WO2011112087A1 (en) 2010-03-11 2011-09-15 N.V. Nutricia Controlling the texture of high-protein nutritional compositions comprising micellar casein
US20110257089A1 (en) * 2008-10-24 2011-10-20 N.V. Nutricia Liquid high-fat protein composition
WO2011151060A1 (en) * 2010-06-04 2011-12-08 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
WO2012005582A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
US8114441B2 (en) 2004-08-20 2012-02-14 N.V. Nutricia Immune stimulatory infant nutrition
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
US8277836B2 (en) 1998-08-11 2012-10-02 N.V. Nutricia Carbohydrates mixture
US8283335B2 (en) 2007-06-26 2012-10-09 N.V. Nutricia Lipid composition for improving brain function
US8282965B2 (en) 2007-12-20 2012-10-09 N.V. Nutricia Liquid nucleotides/nucleosides-containing product
US8287931B2 (en) 2005-06-30 2012-10-16 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
US8293264B2 (en) 2009-05-11 2012-10-23 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
EP2526784A1 (en) * 2011-05-24 2012-11-28 Nestec S.A. Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
WO2013012313A1 (en) 2011-07-18 2013-01-24 N.V. Nutricia Use of a nucleotide for improving the heat stability of an aqueous micellar casein composition
US8361989B2 (en) 2007-06-26 2013-01-29 N. V. Nutricia Supporting activities of daily living
WO2013025104A1 (en) 2011-08-16 2013-02-21 Friesland Brands B.V. Nutritional compositions comprising human milk oligosaccharides and uses thereof
US8409651B2 (en) 2007-12-05 2013-04-02 N. V. Nutricia High energy liquid enteral nutritional composition
US8425955B2 (en) 2009-02-12 2013-04-23 Mead Johnson Nutrition Company Nutritional composition with prebiotic component
US8445458B2 (en) 2007-06-27 2013-05-21 N. V. Nutricia Food composition for prodromal dementia patients
JP2013150635A (en) * 2013-05-01 2013-08-08 Hayashibara Co Ltd Orally ingestible composition for diet
WO2013117235A1 (en) * 2012-02-10 2013-08-15 N.V. Nutricia Maternal supplement to enhance immune system of an infant
WO2013117234A1 (en) * 2012-02-10 2013-08-15 N.V. Nutricia Maternal composition for enhancing immune system
WO2013126015A1 (en) 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
WO2013129925A1 (en) 2012-02-28 2013-09-06 N.V. Nutricia Energy-rich liquid nutritional composition having improved organoleptic properties
CN103315205A (en) * 2006-03-10 2013-09-25 纽崔西亚公司 Use of non-digestable sacharides for giving an infant the best start after birth
WO2013172714A1 (en) 2012-05-18 2013-11-21 N.V. Nutricia Treatment of conditions associated with mycotoxin exposure
EP2695528A1 (en) 2008-07-02 2014-02-12 N.V. Nutricia Nutritional composition for improving muscle function and daily activity
EP2073647B2 (en) † 2006-10-17 2014-08-13 N.V. Nutricia Ketogenic diet
US8815797B2 (en) 2008-03-12 2014-08-26 N.V. Nutricia High protein liquid enteral nutritional composition
US8986769B2 (en) 2008-10-24 2015-03-24 Mead Johnson Nutrition Company Methods for preserving endogenous TGF-β
WO2016013935A1 (en) 2014-07-24 2016-01-28 N.V. Nutricia Prevention or treatment of food allergy in infants and toddlers
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
WO2016086208A1 (en) 2014-11-25 2016-06-02 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
EP3097791A1 (en) * 2010-06-04 2016-11-30 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
EP2077728B1 (en) 2006-11-02 2016-12-21 N.V. Nutricia Use of nutritional compositions for preventing disorders
US9617327B2 (en) 2012-06-14 2017-04-11 N.V. Nutricia Fermented infant formula with non digestible oligosaccharides
WO2017079450A1 (en) 2015-11-03 2017-05-11 The Brigham And Women's Hospital Therapeutic microbiota for the treatment and/or prevention of food allergy
EP3216349A1 (en) 2007-12-05 2017-09-13 N.V. Nutricia Protein-dense micellar casein-based liquid enteral nutritional composition
WO2018023003A1 (en) * 2016-07-29 2018-02-01 Isothrive Llc Optimized individualized prebiotic compositions
US9961932B2 (en) 2013-06-10 2018-05-08 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
WO2018162619A1 (en) 2017-03-08 2018-09-13 N.V. Nutricia Composition with non-digestible oligosaccharides for attenuating nasal epithelial inflammation
US10124016B2 (en) 2008-06-13 2018-11-13 N.V. Nutricia Immune system stimulating nutrition
EP3114943B1 (en) 2006-08-04 2019-02-27 N.V. Nutricia Non-allergenic food product
EP3508075A1 (en) * 2010-06-04 2019-07-10 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
RU2773674C2 (en) * 2009-07-15 2022-06-07 Н.В. Нютрисиа Mixture of indigestible oligosaccharides to stimulate immune system
US11395810B2 (en) 2007-06-26 2022-07-26 N.V. Nutricia Memory in subjects with mini-mental state examination of 24-26
US11559539B2 (en) 2017-08-11 2023-01-24 N.V. Nutricia Human milk oligosaccharide for improving immune fitness

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
JP2006298783A (en) * 2005-04-18 2006-11-02 Nisshin Sugar Mfg Co Ltd Immunostimulating composition
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
KR101243406B1 (en) * 2008-01-09 2013-03-13 뉴트리 가부시키가이샤 Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy
WO2009096772A1 (en) 2008-02-01 2009-08-06 N.V. Nutricia Composition for stimulating natural killer cell activity
CA2752800C (en) 2009-02-24 2017-12-05 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
CN101637264B (en) * 2009-08-20 2012-11-14 辽宁大学 Oligosaccharide probiotics
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
EP2673050B1 (en) * 2011-02-10 2016-03-30 Alfa Biogene International B.V. Plant hsp70 for use in the treatment of food allergy
GB201208325D0 (en) 2012-05-11 2012-06-27 Glycomar Ltd Saccharides
WO2014030250A1 (en) * 2012-08-24 2014-02-27 カクイ株式会社 Antitumor agent
JP5841168B2 (en) * 2012-08-24 2016-01-13 カクイ株式会社 Antitumor agent
JP6160011B2 (en) * 2013-02-06 2017-07-12 松谷化学工業株式会社 IgA secretion promoter
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US20160206728A1 (en) * 2013-10-03 2016-07-21 Nitto Denko Corporation Dried influenza vaccine preparation and method of producing the same
CN104055784A (en) * 2014-06-24 2014-09-24 刘斌 Allergy prevention composition for infant
AU2017326654C1 (en) * 2016-09-19 2022-07-21 Prolacta Bioscience, Inc. Purified human milk oligosaccharides compositions
US11612578B2 (en) * 2016-11-16 2023-03-28 Fresenius Kabi Deutschland Gmbh Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients
EP3993759A4 (en) * 2019-07-05 2023-10-18 Coste, Fanny Prebiotic cosmetic compositions and methods for the preparation thereof
CN113072601B (en) * 2021-03-30 2023-03-31 固安君德同创生物工程有限公司 Preparation method and application of functional oligosaccharide glycoside ester
AU2022487694A1 (en) * 2023-04-05 2024-10-24 Sigilon Therapeutics, Inc. Modified polysaccharide polymers and related compositions and methods thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1327740A (en) * 1971-03-26 1973-08-22 Rit Rech Ind Therapeut Vaccine preparations containing adjuvants
US4412946A (en) * 1980-09-19 1983-11-01 Roussel Uclaf Immunostimulating glycoproteins
EP0406685A1 (en) * 1989-07-01 1991-01-09 Hoechst Aktiengesellschaft Substituted polysaccharides, method for their preparation as well as their use in prophylaxis and treatment of viral diseases
FR2781673A1 (en) * 1998-07-28 2000-02-04 Univ Picardie Use of glucuronan oligo- or polysaccharides, especially produced by Rhizobium meliloti, as cytokine production stimulants for preparing immunostimulant agents
WO2000057727A1 (en) * 1999-03-26 2000-10-05 N.V. Nutricia Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions
WO2001033975A1 (en) * 1999-09-29 2001-05-17 N.V. Nutricia Nutritional compositions which contain non-digestible polysaccharides and use thereof to reduce transport through tight junctions
WO2002042484A2 (en) * 2000-11-22 2002-05-30 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Method for producing pectin hydrolysis products
WO2002047703A2 (en) * 2000-12-11 2002-06-20 Nutricia N.V. Immune system stimulation
US20030022863A1 (en) * 2000-02-16 2003-01-30 Bernd Stahl Antiadhesive carbohydrates
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584724A (en) * 1981-07-01 1983-01-11 Meiji Milk Prod Co Ltd Immunological activating agent
WO1985005031A1 (en) * 1984-05-09 1985-11-21 The Australian National University A method for the modulation of the immune response
JPH0714885B2 (en) * 1986-05-20 1995-02-22 野田食菌工業株式会社 Immunoactive substance
JPH04300888A (en) * 1991-03-28 1992-10-23 Dainippon Ink & Chem Inc Carboxylic acid oligosaccharide ester sulfate
DE4141970C2 (en) * 1991-12-16 1998-02-19 Charite Med Fakultaet Combination vaccine against AIDS, schistosomiasis and tuberculosis and process for its preparation
DE4223613C2 (en) 1992-07-17 1994-07-21 Zuckerindustrie Verein Process for the production of unsaturated uronides from pectin-containing substances
JP3568214B2 (en) * 1993-03-03 2004-09-22 昭和産業株式会社 Immunostimulants
KR970011556B1 (en) * 1993-12-20 1997-07-12 농촌진흥청 Purification method of fomitella fraxinea rdagb 129 extracts
JPH0892303A (en) 1994-09-20 1996-04-09 Showa Sangyo Co Ltd New saccharide, its production and immunopotentiator
JPH0948732A (en) 1995-08-04 1997-02-18 Pola Chem Ind Inc Activated oxygen scavenging agent and composition containing the same
JP3850908B2 (en) 1996-01-30 2006-11-29 ポーラ化成工業株式会社 Glucose level rise inhibitor and composition containing the same
FR2751876B1 (en) * 1996-07-31 1998-12-31 Roc Sa USE OF AN OLIGOSACCHARIDE AS AN IMMUNOMODULATOR, DERMATO-COSMETIC COMPOSITION AND METHOD OF COSMETIC TREATMENT
DE19701382A1 (en) 1997-01-16 1998-07-23 Nutricia Nv Carbohydrate mix
KR100252194B1 (en) * 1997-10-10 2000-04-15 박호군 Novel pectin type polysaccharide from Angelica gigas Nakai, purification process thereof
DE19836339B4 (en) 1998-08-11 2011-12-22 N.V. Nutricia carbohydrate mix
DE19940011B4 (en) * 1999-08-24 2009-04-02 Schütte/Reichel GbR (vertretungsberechtigte Gesellschafter: Irene Schütte Alginate preparation and their use
JP4024454B2 (en) * 2000-03-31 2007-12-19 日本甜菜製糖株式会社 IgE antibody production reducing agent and allergic constitution improving agent
JP2004513071A (en) * 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Method of treating respiratory disease associated with elastic fiber injury of the lung
DE10027050A1 (en) * 2000-06-02 2001-12-13 Karim Balan Therapeutic composition containing alginate preparation and plant extract, useful e.g. for immunomodulation or treatment of gastrointestinal disorders, migraine, rheumatism or diabetes
JPWO2002018614A1 (en) * 2000-08-30 2004-09-30 天野エンザイム株式会社 Method for increasing yield of oligosaccharide containing α-galactosyl group and anti-candida composition
CN1111541C (en) * 2000-09-15 2003-06-18 青岛海洋大学 Polymannuronic acid sulfate
JP2002363082A (en) * 2001-05-28 2002-12-18 Yoshiaki Nagaura Method for inactivating virus
KR100450061B1 (en) * 2001-06-13 2004-09-24 주식회사 한국인삼공사 Novel acid polysaccharide having anti-cancer immunoregulatory effect which is purified from red ginseng and composition for anti-cancer immunoreguation comprising same
US20030078231A1 (en) * 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
US20030007961A1 (en) * 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
JP4053743B2 (en) * 2001-07-27 2008-02-27 株式会社ファンケル Immunomodulator
JP2003221339A (en) * 2002-01-29 2003-08-05 Oji Paper Co Ltd Anti-inflammatory agent
US6946451B2 (en) 2002-02-04 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Insulin secretion promoter
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
ES2324369T3 (en) 2003-10-24 2009-08-05 N.V. Nutricia IMMUNOMODULATING OLIGOSACARIDS.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1327740A (en) * 1971-03-26 1973-08-22 Rit Rech Ind Therapeut Vaccine preparations containing adjuvants
US4412946A (en) * 1980-09-19 1983-11-01 Roussel Uclaf Immunostimulating glycoproteins
EP0406685A1 (en) * 1989-07-01 1991-01-09 Hoechst Aktiengesellschaft Substituted polysaccharides, method for their preparation as well as their use in prophylaxis and treatment of viral diseases
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
FR2781673A1 (en) * 1998-07-28 2000-02-04 Univ Picardie Use of glucuronan oligo- or polysaccharides, especially produced by Rhizobium meliloti, as cytokine production stimulants for preparing immunostimulant agents
WO2000057727A1 (en) * 1999-03-26 2000-10-05 N.V. Nutricia Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions
WO2001033975A1 (en) * 1999-09-29 2001-05-17 N.V. Nutricia Nutritional compositions which contain non-digestible polysaccharides and use thereof to reduce transport through tight junctions
US20030022863A1 (en) * 2000-02-16 2003-01-30 Bernd Stahl Antiadhesive carbohydrates
WO2002042484A2 (en) * 2000-11-22 2002-05-30 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Method for producing pectin hydrolysis products
WO2002047703A2 (en) * 2000-12-11 2002-06-20 Nutricia N.V. Immune system stimulation

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; XP002277425 & KR 9 711 556 B (RURAL DEV ADMIN) 12 July 1997 (1997-07-12) *
DATABASE WPI Section Ch, Week 198307 Derwent Publications Ltd., London, GB; Class A96, AN 1983-16545K XP002277416 & JP 58 004724 A (MEIJI MILK PROD CO LTD) 11 January 1983 (1983-01-11) *
DATABASE WPI Section Ch, Week 199249 Derwent Publications Ltd., London, GB; Class A96, AN 1992-403412 XP002277418 & JP 04 300888 A (DAINIPPON INK & CHEM KK) 23 October 1992 (1992-10-23) *
DATABASE WPI Section Ch, Week 199441 Derwent Publications Ltd., London, GB; Class B04, AN 1994-329946 XP002277419 & JP 06 256208 A (FOOD DESIGN GIJUTSU KENKYU KUMIAI) 13 September 1994 (1994-09-13) *
DATABASE WPI Section Ch, Week 199624 Derwent Publications Ltd., London, GB; Class B04, AN 1996-236112 XP002277420 & JP 08 092303 A (SHOWA SANGYO CO) 9 April 1996 (1996-04-09) *
DATABASE WPI Section Ch, Week 200332 Derwent Publications Ltd., London, GB; Class B03, AN 2003-339110 XP002277417 & KR 2002 094 725 A (KT & G CO LTD) 18 December 2002 (2002-12-18) *
KULKARNI SAVITA ET AL: "Immunostimulant activity of inulin isolated from Saussurea lappa roots." INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 63, no. 4, July 2001 (2001-07), pages 292-294, XP009029650 ISSN: 0250-474X *
PATENT ABSTRACTS OF JAPAN vol. 012, no. 159 (C-495), 14 May 1988 (1988-05-14) & JP 62 270532 A (NODA SHIYOKUKIN KOGYO KK;OTHERS: 01), 24 November 1987 (1987-11-24) *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 06, 30 June 1997 (1997-06-30) & JP 09 048732 A (POLA CHEM IND INC), 18 February 1997 (1997-02-18) *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 12, 25 December 1997 (1997-12-25) & JP 09 208474 A (POLA CHEM IND INC), 12 August 1997 (1997-08-12) *
ZAPOROZHETS T S ET AL: "[Immunomodulating properties of pectin from seawater grass Zostera]" ANTIBIOTIKI I KHIMIOTERAPIIA = ANTIBIOTICS AND CHEMOTERAPY [SIC] / MINISTERSTVO MEDITSINSKOI I MIKROBIOLOGICHESKOI PROMYSHLENNOSTI SSSR. USSR AUG 1991, vol. 36, no. 8, August 1991 (1991-08), pages 31-34, XP009028863 ISSN: 0235-2990 *

Cited By (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580295B2 (en) 1998-08-11 2013-11-12 N.V. Nutricia Carbohydrates mixture
US8277836B2 (en) 1998-08-11 2012-10-02 N.V. Nutricia Carbohydrates mixture
US9763466B2 (en) 1998-08-11 2017-09-19 N.V. Nutricia Carbohydrates mixture
US8557794B2 (en) 2003-10-24 2013-10-15 N.V. Nutricia Immunemodulating oligosaccharides
EP2223691A1 (en) * 2003-10-24 2010-09-01 N.V. Nutricia Immunemodulating oligosaccharides
CN1871015B (en) * 2003-10-24 2010-06-16 努特里奇亚有限公司 Immunemodulating oligosaccharides
EP1733730A3 (en) * 2003-10-24 2006-12-27 N.V. Nutricia Immunemodulating oligosaccharides
EP1927292A1 (en) 2004-05-17 2008-06-04 N.V. Nutricia Synergism of GOS and polyfructose
US10426791B2 (en) 2004-05-17 2019-10-01 N.V. Nutricia Synergism of GOS and polyfructose
EP1685763A1 (en) * 2004-05-17 2006-08-02 N.V. Nutricia Synergism of GOS and polyfructose
AU2010241530B2 (en) * 2004-05-17 2013-02-14 N.V. Nutricia Synergism of GOS and Polyfructose
US9084433B2 (en) 2004-06-06 2015-07-21 N. V. Nutricia Intestinal barrier integrity
US10499676B2 (en) 2004-06-06 2019-12-10 N.V. Nutricia Intestinal barrier integrity
US11076623B2 (en) 2004-06-22 2021-08-03 N.V. Nutricia Intestinal barrier integrity
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
US8114441B2 (en) 2004-08-20 2012-02-14 N.V. Nutricia Immune stimulatory infant nutrition
US8580316B2 (en) 2004-08-20 2013-11-12 N. V. Nutricia Immune stimulatory infant nutrition
WO2006112717A3 (en) * 2005-04-21 2007-07-12 Nutricia Nv Nutritional supplement for a category of hiv patients
WO2006112716A3 (en) * 2005-04-21 2007-05-10 Nutricia Nv Nutritional supplement for hiv patients
EP1723951A1 (en) * 2005-04-21 2006-11-22 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
EP2241196B2 (en) † 2005-04-21 2017-04-05 N.V. Nutricia Nutritional supplement comprising oligosaccharides and cysteine for treating hiv
EP2241196B1 (en) † 2005-04-21 2012-08-22 N.V. Nutricia Nutritional supplement comprising oligosaccharides and cysteine for treating HIV
EP1721611A1 (en) * 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
WO2006112716A2 (en) * 2005-04-21 2006-10-26 N.V. Nutricia Nutritional supplement for hiv patients
WO2006112717A2 (en) * 2005-04-21 2006-10-26 N.V. Nutricia Nutritional supplement for a category of hiv patients
US8277863B2 (en) 2005-06-01 2012-10-02 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8021708B2 (en) 2005-06-01 2011-09-20 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides
US8557320B2 (en) 2005-06-01 2013-10-15 Mead Johnson Nutrition Company Nutritional composition having prebiotic
US8287932B2 (en) 2005-06-30 2012-10-16 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
US8287931B2 (en) 2005-06-30 2012-10-16 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
US9439448B2 (en) 2005-06-30 2016-09-13 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
WO2007009776A1 (en) * 2005-07-20 2007-01-25 N.V. Nutricia Process for preparing uronic acid oligosaccharides by extrusion
EP1745705A1 (en) * 2005-07-20 2007-01-24 N.V. Nutricia Process for preparing uronic acid oligosaccharides by extrusion
US9585416B2 (en) 2005-10-21 2017-03-07 N.V. Nutricia Preventing diseases in infants delivered via caesarean section
US9107438B2 (en) 2005-10-21 2015-08-18 N.V. Nutricia Preventing diseases in infants delivered via caesarean section
CN102919663A (en) * 2005-10-21 2013-02-13 荷兰纽迪希亚公司 Preventing diseases in infants delivered via caesarean section
WO2007046697A1 (en) * 2005-10-21 2007-04-26 N.V. Nutricia Method for treating and/or preventing infections in infants delivered via caesarean section
JP2009512686A (en) * 2005-10-21 2009-03-26 エヌ．ブイ．・ヌートリシア Disease prevention in infants delivered by cesarean section
WO2007046698A1 (en) * 2005-10-21 2007-04-26 N.V. Nutricia Preventing diseases in infants delivered via caesarean section
CN101330838B (en) * 2005-10-21 2013-01-23 荷兰纽迪希亚公司 Method for preventing diseases in infants delivered via caesarean section
US9596876B2 (en) 2005-10-21 2017-03-21 N. V. Nutricia Method for stimulating the intestinal flora
CN102919663B (en) * 2005-10-21 2015-08-19 荷兰纽迪希亚公司 The method of the diseases in infants of prevention cesarean section delivery
US8715769B2 (en) 2005-10-21 2014-05-06 N.V. Nutricia Preventing diseases in infants delivered via caesarean section
CN101336108A (en) * 2005-12-06 2008-12-31 纽崔西亚公司 Composition containing oligosaccharides for the treatment / prevention of infections
WO2007067033A1 (en) * 2005-12-06 2007-06-14 N.V. Nutricia Composition containing oligosaccharides for the treatment/ prevention of infections
AU2006323322B2 (en) * 2005-12-06 2012-08-09 N.V. Nutricia Composition containing oligosaccharides for the treatment / prevention of infections
WO2007067053A1 (en) 2005-12-06 2007-06-14 N.V. Nutricia Composition containing oligosaccharides for the treatment / prevention of infections
WO2007069900A1 (en) 2005-12-16 2007-06-21 N.V. Nutricia Use of soluble dietary fibres against muscle wasting
US8143235B2 (en) 2005-12-16 2012-03-27 N.V. Nutricia Use of dietary fibres against muscle wasting
US20120165243A1 (en) * 2005-12-16 2012-06-28 N. V. Nutricia Use of dietary fibres against muscle wasting
AU2006325591B2 (en) * 2005-12-16 2012-07-12 N.V. Nutricia Use of soluble dietary fibres against muscle wasting
US9555059B2 (en) 2005-12-16 2017-01-31 N.V. Nutricia Use of dietary fibres against muscle wasting
JP2009519328A (en) * 2005-12-16 2009-05-14 エヌ．ブイ．・ヌートリシア Use of soluble dietary fiber for muscle atrophy
US20090297636A1 (en) * 2006-02-07 2009-12-03 Martine Sandra Alles Sensoric imprinting
US20140234475A1 (en) * 2006-02-07 2014-08-21 N.V. Nutricia Sensoric imprinting
US8361530B2 (en) 2006-02-10 2013-01-29 Nestec S.A. Oligosaccharide mixture
WO2007090894A1 (en) * 2006-02-10 2007-08-16 Nestec S.A. Oligosaccharide mixture
CN103315205A (en) * 2006-03-10 2013-09-25 纽崔西亚公司 Use of non-digestable sacharides for giving an infant the best start after birth
WO2007114696A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
US8754064B2 (en) 2006-03-30 2014-06-17 N.V. Nutricia Milk oligosaccharide for stimulating the immune system
WO2008010428A1 (en) * 2006-07-19 2008-01-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Immunomodulating agent
JP5289952B2 (en) * 2006-07-19 2013-09-11 株式会社林原 Immunomodulator
EP3114943B1 (en) 2006-08-04 2019-02-27 N.V. Nutricia Non-allergenic food product
EP2073647B2 (en) † 2006-10-17 2014-08-13 N.V. Nutricia Ketogenic diet
EP2077728B1 (en) 2006-11-02 2016-12-21 N.V. Nutricia Use of nutritional compositions for preventing disorders
JP2008247858A (en) * 2007-03-30 2008-10-16 Hayashibara Biochem Lab Inc Dietary composition for oral administration
US8283335B2 (en) 2007-06-26 2012-10-09 N.V. Nutricia Lipid composition for improving brain function
US8759319B2 (en) 2007-06-26 2014-06-24 N.V. Nutricia Lipid composition for improving brain function
US8361989B2 (en) 2007-06-26 2013-01-29 N. V. Nutricia Supporting activities of daily living
US8791089B2 (en) 2007-06-26 2014-07-29 N.V. Nutricia Supporting activities of daily living
US11395810B2 (en) 2007-06-26 2022-07-26 N.V. Nutricia Memory in subjects with mini-mental state examination of 24-26
US8445458B2 (en) 2007-06-27 2013-05-21 N. V. Nutricia Food composition for prodromal dementia patients
US8409651B2 (en) 2007-12-05 2013-04-02 N. V. Nutricia High energy liquid enteral nutritional composition
EP2687106A1 (en) 2007-12-05 2014-01-22 N.V. Nutricia High energy liquid enteral nutritional composition
EP2818055A1 (en) 2007-12-05 2014-12-31 N.V. Nutricia High energy liquid enteral nutritional composition
US9345256B2 (en) 2007-12-05 2016-05-24 N.V. Nutricia High energy liquid enteral nutritional composition
EP3216349A1 (en) 2007-12-05 2017-09-13 N.V. Nutricia Protein-dense micellar casein-based liquid enteral nutritional composition
US8999423B2 (en) 2007-12-05 2015-04-07 N. V. Nutricia High energy liquid enteral nutritional composition
EP2818055B1 (en) 2007-12-05 2020-10-28 N.V. Nutricia High energy liquid enteral nutritional composition
US8604000B2 (en) 2007-12-20 2013-12-10 N.V. Nutricia Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent
US9132196B2 (en) 2007-12-20 2015-09-15 N. V. Nutricia Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent
US9687555B2 (en) 2007-12-20 2017-06-27 N.V. Nutricia Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent
US8282965B2 (en) 2007-12-20 2012-10-09 N.V. Nutricia Liquid nucleotides/nucleosides-containing product
US9420816B2 (en) 2008-03-12 2016-08-23 N.V. Nutricia High protein liquid enteral nutritional composition
US8815797B2 (en) 2008-03-12 2014-08-26 N.V. Nutricia High protein liquid enteral nutritional composition
US10124016B2 (en) 2008-06-13 2018-11-13 N.V. Nutricia Immune system stimulating nutrition
EP2695528A1 (en) 2008-07-02 2014-02-12 N.V. Nutricia Nutritional composition for improving muscle function and daily activity
EP3906788A1 (en) 2008-07-02 2021-11-10 N.V. Nutricia Nutritional composition for providing a better prognosis in terms of extended life-expectancy
US8986769B2 (en) 2008-10-24 2015-03-24 Mead Johnson Nutrition Company Methods for preserving endogenous TGF-β
US9386794B2 (en) 2008-10-24 2016-07-12 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
US20110257089A1 (en) * 2008-10-24 2011-10-20 N.V. Nutricia Liquid high-fat protein composition
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
US8425955B2 (en) 2009-02-12 2013-04-23 Mead Johnson Nutrition Company Nutritional composition with prebiotic component
WO2010095943A2 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of resveratrol or another hydroxylated stilbene for preserving cognitive functioning
WO2010104394A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US8293264B2 (en) 2009-05-11 2012-10-23 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
EP2954787A1 (en) 2009-06-05 2015-12-16 N.V. Nutricia Liquid enteral nutritional composition with a low monovalent metal ion content
EP4136986A1 (en) 2009-06-05 2023-02-22 N.V. Nutricia Liquid enteral nutritional composition with a low monovalent metal ion content
WO2010140891A2 (en) 2009-06-05 2010-12-09 N.V. Nutricia Liquid enteral nutritional composition with a low monovalent metal ion content
US8591919B2 (en) 2009-06-12 2013-11-26 N.V. Nutricia Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta -1,4/1,6 linkages
WO2010143961A1 (en) 2009-06-12 2010-12-16 N.V. Nutricia Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages
EP2662084A1 (en) 2009-07-15 2013-11-13 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
US10588965B2 (en) 2009-07-15 2020-03-17 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
EP4197542A1 (en) * 2009-07-15 2023-06-21 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide for use in enhancing vaccination response
EP2813230A1 (en) * 2009-07-15 2014-12-17 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing infections
RU2794127C2 (en) * 2009-07-15 2023-04-11 Н.В. Нютрисиа Indigestible oligosaccharide mixture for stimulation of immune system
WO2011008087A1 (en) * 2009-07-15 2011-01-20 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
WO2011008086A1 (en) 2009-07-15 2011-01-20 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
RU2773674C2 (en) * 2009-07-15 2022-06-07 Н.В. Нютрисиа Mixture of indigestible oligosaccharides to stimulate immune system
EP3932410A1 (en) 2009-07-15 2022-01-05 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
CN106890329A (en) * 2009-07-15 2017-06-27 N·V·努特里奇亚 For the mixture of the indigestible oligosaccharide of stimulating immune system
US11135290B2 (en) 2009-07-15 2021-10-05 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US11090321B2 (en) 2009-07-15 2021-08-17 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
CN102497868A (en) * 2009-07-15 2012-06-13 N.V.努特里奇亚 Mixture of non-digestible oligosaccharides for stimulating the immune system
RU2591831C2 (en) * 2009-07-15 2016-07-20 Н.В. Нютрисиа Mixture of indigestible oligosaccharides to stimulate immune system
CN107087793A (en) * 2009-07-15 2017-08-25 N·V·努特里奇亚 Mixture for the indigestible oligosaccharide of stimulating immune system
US10420784B2 (en) 2009-07-15 2019-09-24 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
EP3342413A1 (en) * 2009-07-15 2018-07-04 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing viral diarrhoea
EP2865382A1 (en) 2009-12-24 2015-04-29 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
WO2011078654A1 (en) 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
WO2011078677A2 (en) 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
WO2011112075A1 (en) 2010-03-11 2011-09-15 N.V. Nutricia Controlling the texture of high-protein nutritional compositions comprising micellar casein
EP2732710A1 (en) 2010-03-11 2014-05-21 N.V. Nutricia Controlling the texture of high-protein nutritional compositions comprising micellar casein
WO2011112087A1 (en) 2010-03-11 2011-09-15 N.V. Nutricia Controlling the texture of high-protein nutritional compositions comprising micellar casein
WO2011151059A1 (en) * 2010-06-04 2011-12-08 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
EP3508075A1 (en) * 2010-06-04 2019-07-10 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
EP3097791A1 (en) * 2010-06-04 2016-11-30 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
WO2011150949A1 (en) * 2010-06-04 2011-12-08 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
US9119838B2 (en) 2010-06-04 2015-09-01 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
EP3338565A1 (en) * 2010-06-04 2018-06-27 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
WO2011151060A1 (en) * 2010-06-04 2011-12-08 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
US9060996B2 (en) 2010-06-04 2015-06-23 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
US9770460B2 (en) 2010-06-04 2017-09-26 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
US10045999B2 (en) 2010-07-07 2018-08-14 N. V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
WO2012005582A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
US9089157B2 (en) 2010-07-26 2015-07-28 Mead Johnson Nutrition Company Adherence inhibition of pathogens by prebiotic oligosaccharides
EP2526784A1 (en) * 2011-05-24 2012-11-28 Nestec S.A. Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
WO2012160080A1 (en) * 2011-05-24 2012-11-29 Nestec S.A. Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
WO2013012313A1 (en) 2011-07-18 2013-01-24 N.V. Nutricia Use of a nucleotide for improving the heat stability of an aqueous micellar casein composition
WO2013012324A1 (en) 2011-07-18 2013-01-24 N.V. Nutricia Use of a nucleotide for improving the heat stability of an aqueous micellar casein composition
WO2013025104A1 (en) 2011-08-16 2013-02-21 Friesland Brands B.V. Nutritional compositions comprising human milk oligosaccharides and uses thereof
EP3075383A1 (en) * 2012-02-10 2016-10-05 N.V. Nutricia Maternal supplement to enhance immune system of an infant
WO2013117234A1 (en) * 2012-02-10 2013-08-15 N.V. Nutricia Maternal composition for enhancing immune system
RU2586150C2 (en) * 2012-02-10 2016-06-10 Н.В. Нутриция Additive for mother intended for reinforcing the immune system of a child
WO2013117235A1 (en) * 2012-02-10 2013-08-15 N.V. Nutricia Maternal supplement to enhance immune system of an infant
EP2811845B1 (en) 2012-02-10 2015-12-09 N.V. Nutricia Maternal supplement to enhance immune system of an infant
WO2013126015A1 (en) 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
WO2013129925A1 (en) 2012-02-28 2013-09-06 N.V. Nutricia Energy-rich liquid nutritional composition having improved organoleptic properties
WO2013129912A1 (en) 2012-02-28 2013-09-06 N.V. Nutricia Energy-rich liquid nutritional composition having improved organoleptic properties
WO2013172714A1 (en) 2012-05-18 2013-11-21 N.V. Nutricia Treatment of conditions associated with mycotoxin exposure
US9717270B2 (en) 2012-06-14 2017-08-01 N.V. Nutricia Fermented infant formula with non digestible oligosaccharides
US9617327B2 (en) 2012-06-14 2017-04-11 N.V. Nutricia Fermented infant formula with non digestible oligosaccharides
JP2013150635A (en) * 2013-05-01 2013-08-08 Hayashibara Co Ltd Orally ingestible composition for diet
US9961932B2 (en) 2013-06-10 2018-05-08 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
WO2016013928A1 (en) 2014-07-24 2016-01-28 N.V. Nutricia Prevention or treatment of food allergy in infants and toddlers
WO2016013935A1 (en) 2014-07-24 2016-01-28 N.V. Nutricia Prevention or treatment of food allergy in infants and toddlers
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
WO2016086205A2 (en) 2014-11-25 2016-06-02 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome
WO2016086206A1 (en) 2014-11-25 2016-06-02 Epiva Biosciences, Inc. Probiotic compositions containing clostridials for inhibiting inflammation
EP3747450A1 (en) 2014-11-25 2020-12-09 Evelo Biosciences, Inc. Pharmaceutical composition consisting of blautia, for oral administration
WO2016086208A1 (en) 2014-11-25 2016-06-02 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
WO2016086210A1 (en) 2014-11-25 2016-06-02 Epiva Biosciences, Inc. Probiotic and prebiotic compostions, and methods of use therof for treatment and prevention of graft versus host disease
US10391131B2 (en) 2015-11-03 2019-08-27 The Brigham And Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
US10265349B2 (en) 2015-11-03 2019-04-23 The Brigham And Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
EP4066846A1 (en) 2015-11-03 2022-10-05 The Brigham & Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
US10898527B2 (en) 2015-11-03 2021-01-26 The Brigham And Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
WO2017079450A1 (en) 2015-11-03 2017-05-11 The Brigham And Women's Hospital Therapeutic microbiota for the treatment and/or prevention of food allergy
WO2018023003A1 (en) * 2016-07-29 2018-02-01 Isothrive Llc Optimized individualized prebiotic compositions
WO2018162619A1 (en) 2017-03-08 2018-09-13 N.V. Nutricia Composition with non-digestible oligosaccharides for attenuating nasal epithelial inflammation
US12023347B2 (en) 2017-03-08 2024-07-02 Van Bergenhenegouwen Jeroen Composition with non-digestible oligosaccharides for attenuating nasal epithelial inflammation
US11559539B2 (en) 2017-08-11 2023-01-24 N.V. Nutricia Human milk oligosaccharide for improving immune fitness

Also Published As

Publication number Publication date
SG152271A1 (en) 2009-05-29
PT1721612E (en) 2009-09-02
EP1911453A3 (en) 2008-09-03
SI1721612T1 (en) 2009-08-31
EP1733730A3 (en) 2006-12-27
CA2542996C (en) 2014-05-27
EP2123282A2 (en) 2009-11-25
EP2223691A1 (en) 2010-09-01
DK1733730T3 (en) 2008-10-13
RU2010102704A (en) 2011-08-10
EP2305269A3 (en) 2011-07-13
DE602004014992D1 (en) 2008-08-21
ES2309901T3 (en) 2008-12-16
DE602004020809D1 (en) 2009-06-04
AU2004283628B2 (en) 2010-07-22
NZ546785A (en) 2009-07-31
AU2010235987A1 (en) 2010-11-11
CN101987107A (en) 2011-03-23
EP1721612B1 (en) 2009-04-22
EP2305269A2 (en) 2011-04-06
EP2305269B1 (en) 2020-01-15
EP1935425A2 (en) 2008-06-25
ATE429232T1 (en) 2009-05-15
BRPI0415699A (en) 2006-12-26
EP1675595A2 (en) 2006-07-05
PL1733730T3 (en) 2008-12-31
CA2542996A1 (en) 2005-05-06
US20070098762A1 (en) 2007-05-03
DK1721612T3 (en) 2009-06-02
JP2007525483A (en) 2007-09-06
WO2005039597A3 (en) 2005-07-14
RU2388478C2 (en) 2010-05-10
EP1935425A3 (en) 2008-09-03
ES2324369T3 (en) 2009-08-05
EP1733730A2 (en) 2006-12-20
CY1108342T1 (en) 2014-02-12
PL1721612T3 (en) 2009-09-30
JP4943853B2 (en) 2012-05-30
ATE400278T1 (en) 2008-07-15
SI1733730T1 (en) 2008-12-31
NZ577220A (en) 2011-01-28
PT1733730E (en) 2008-10-28
SG152270A1 (en) 2009-05-29
AU2004283628A2 (en) 2005-05-06
ES2781848T3 (en) 2020-09-08
RU2006117784A (en) 2007-12-10
EP1721612A2 (en) 2006-11-15
AU2004283628A1 (en) 2005-05-06
EP1733730B1 (en) 2008-07-09
CY1110353T1 (en) 2015-04-29
US8557794B2 (en) 2013-10-15
EP1911453A2 (en) 2008-04-16
EP1721612A3 (en) 2007-05-09
EP2123282A3 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
AU2004283628B2 (en) Immunemodulating oligosaccharides
US11090321B2 (en) Mixture of non-digestible oligosaccharides for stimulating the immune system
RU2426549C2 (en) Immunity-stimulating baby food
EP2813230A1 (en) Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing infections
ZA200603166B (en) Immunemodulating oligosaccharides
MXPA06004523A (en) Immunemodulating oligosaccharides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480031243.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004793675

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2542996

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006/03166

Country of ref document: ZA

Ref document number: 200603166

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2007098762

Country of ref document: US

Ref document number: PA/a/2006/004523

Country of ref document: MX

Ref document number: 546785

Country of ref document: NZ

Ref document number: 10576834

Country of ref document: US

Ref document number: 2006536469

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12006500833

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2004283628

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2769/DELNP/2006

Country of ref document: IN

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006117784

Country of ref document: RU

Ref document number: 1200600822

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2004283628

Country of ref document: AU

Date of ref document: 20041025

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004283628

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004793675

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: PI0415699

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10576834

Country of ref document: US

122 Ep: pct application non-entry in european phase